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SUMMARY 
The complement (C) system is part of the local microenvironment acting as a 
bridge between innate and adaptive immunity and taking part in immune surveillance and 
homeostasis. The C activation is known to inhibit tumour development contributing to the 
destruction of cancer cells. This paradigm have recently been challenged by demonstrating 
a tumour-promoting role for C, which may support chronic inflammation, promote an 
immunosuppressive milieu, induce angiogenesis, and activate cancer-related signalling 
pathways. 
C1q is the first component of the C system, which belongs to the Tumour Necrosis Factor 
superfamily of proteins and is mainly produced by macrophages, fibroblasts and 
endothelial cells. C1q plays a key role in apoptotic cell and immune complex removal. 
Besides activating the classical C pathway, growing evidence demonstrates that C1q has 
other biologic functions, including regulation of autoimmune diseases and promotion of 
angiogenesis and tissue remodelling.  
The role of C1q in the pathogenesis of cancer is still unknown. The first evidence 
supporting a role of C1q in tumour progression has been proposed by Markiewski and 
colleagues, who interpreted the localization of C1q on tumour vessels in a mouse model of 
cervical carcinoma as an indication of C activation through the classical pathway.  
We decided to investigate the contribution of C1q to cancer development following our 
previous finding that C1q is deeply involved in trophoblast invasion and placental 
development. The invasive behaviour of trophoblast resembles that of cancer cells, except 
that this is a physiological process, tightly regulated in time and space. 
Our analysis of several solid human tumours revealed the presence of C1q that was 
distributed on the vascular endothelium and in the stroma in the absence of C4. The 
tumours were mildly positive for C3 and C1s. Analysis of melanoma and colon 
adenocarcinoma development revealed expression of C1q in a very early stage of 
malignant transformation. Overall, the data support a tumour-promoting role of C1q 
independently of classical C pathway activation. 
C1qa-/- B16/F10 melanoma-bearing mice show inhibition of the tumour growth and 
increased survival rate compared to WT, C3-/- and C5-/- mice. Analysis of the tumour mass 
confirm the presence of C1q, but not C4, on vessels and in the tumour stroma. C3 was also 
detected mainly associated with tumour-infiltrating macrophages. 
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Analysis of growing murine melanoma revealed that C1q appeared earlier than C3 in the 
tumour mass and was only partially co-localized with CD68+ infiltrating cells, clearly 
suggesting that C1q was at least in part produced by non-myeloid cells.  
The tumour mass in C1qa-/- melanoma-bearing mice showed reduced microvascular 
density compared to the WT supporting our recent findings that C1q induces angiogenesis 
by promoting wound healing. Moreover, the C1qa-/- mice manifested a lower number of 
lung metastases. No difference was observed in the percentage of tumour-infiltrating 
leukocytes between WT and C1qa-/- mice.  
Bone marrow transplantation between WT and C1qa-/- mice revealed that the C1q-deficient 
background was associated with reduced tumour progression, even in the presence of C1q-
producing myeloid cells in the tumour microenvironment. Analysis of the tumour mass in 
bone marrow transplanted mice clearly showed that tumour vessel endothelium and CD68- 
infiltrating cells mainly contribute to local production of C1q.  
We demonstrated that solid–phase bound C1q is able to increase adhesion, proliferation 
and migration of B16/F10 melanoma cells in vitro, by stimulating the phosphorylation 
status of ERK, Akt and GSK-3β, possibly because of interaction with gC1qR and α4β1 
integrin expressed on these cells. These evidences suggest C1q as an active player in the 
tumour microenvironment able to sustain tumour growth by enhancing several cancer-
related signalling pathways. 
Our data support the conclusion that C1q favours tumour growth and metastases 
facilitating cancer cell seeding and invasion through promotion of angiogenesis. 
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INTRODUCTION 
 
Chapter 1 
 
1.1    Cancer is more than a genetic disease 
Cancer development is a multistep process where genetic changes are 
accumulated, thus progressively transforming cells into a cancerous phenotype. Several 
evidences in literature suggest that the cellular transformation process from the normal to 
the malignant state requires a number of steps wherein these tumourigenic features 
accumulate through somatic genetic alterations. These genetic aberrations are generally 
characterized as either gain of function in oncogenes or as loss of function of tumour 
suppressors. Gain of function mutations often confer new functions or inhibit normal 
regulatory mechanisms, leading to hyper-activation of associated pathways. Conversely, 
loss of function mutations in tumour suppressors inhibit the function of proteins usually 
involved in restraining cellular growth and replication, or response to genetic damage. 
Both gain or loss of function mutations can arise from a variety of mechanisms, including 
point mutations at critical residues within the protein, insertions or deletions that disrupt 
the normal gene structure, as well as variations in gene copy number that lead to aberrant 
expression (Hanahan and Weinberg, 2011). 
Despite the notion that tumours arise through clonal expansion of cells that have acquired 
genetic alterations advantageous for proliferation, survival and metastasis, it is now 
accepted that epigenetic modifications play a key role in generating dynamic tumour 
heterogeneity (You and Jones, 2012). Epigenetic changes affect gene transcription by 
modulating the packaging of chromatin, including DNA methylation, histone variants and 
modifications, nucleosome remodelling as well as small non-coding regulatory RNAs, 
thereby regulating the accessibility of DNA to sequence-specific transcription factors 
(Sharma et al., 2009; Rodríguez-Paredes and Esteller, 2011). During tumour initiation and 
progression, the epigenome goes through multiple alterations, including a genome-wide 
loss of DNA methylation, frequent increases in promoter methylation of CpG islands, 
changes in nucleosome occupancy and modification profiles. More recently, intriguing 
evidence has emerged that genetic and epigenetic mechanisms are not separate events in 
cancer; they intertwine and take advantage of each other during tumourigenesis. 
Alterations in epigenetic mechanisms can lead to genetic mutations and genetic mutations 
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in epigenetic regulators leads to an altered epigenome (You and Jones, 2012). The readout 
of the epigenome variation dictates the diversity in cellular phenotypes of cells harbouring 
the same genome. Furthermore, a specific combination of genetic and epigenetic marks has 
been shown to be able to produce drug-resistant phenotypes in a heterogeneous tumour cell 
population (Wilting and Dannenberg, 2012). The fact that the epigenome acts at the 
pinnacle of the hierarchy of gene control mechanisms, by affecting multiple pathways 
relevant to the cancer phenotype, has reached mainstream oncology in the development of 
new biomarkers of the disease and new pharmacological strategies (Rodríguez-Paredes and 
Esteller, 2011). 
Over the last decades, numerous investigators have studied the underlying molecular 
mechanisms for malignant transformation. This has resulted in many models that explain 
the development of a malignant phenotype of human cells, for instance the “Hallmarks of 
Cancer” by Hanahan and Weinberg (Hanahan and Weinberg, 2011). Cells undergoing 
malignant transformation acquire the ability to sustain proliferative signalling, evade 
growth suppressors, and enable replicative immortality by resisting cell death, promote 
inflammation, induce angiogenesis and deregulate cellular metabolism, avoid immune 
distraction, invade the surrounding tissue and spread to distant organs via the circulatory or 
lymphatic systems (Figure 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Hallmarks of cancer. Malignant tumours have overcome cell intrinsic suppressors of 
carcinogenesis such as apoptosis, scarcity of growth stimuli, anti-proliferative signalling, DNA-repair 
mechanisms and telomere shortening. Extrinsic hallmarks of cancer involve the induction of angiogenesis, 
tissue-remodelling leading to metastasis, evasion of anti-tumour immune responses, as well as the induction 
of tumour promoting inflammation. (Figures adapted from Hanahan and Weinberg, Cell, 2011; 144:646-74). 
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1.2    The role of the microenvironment on the progression of cancer 
There is strong evidence that tumour growth not only depends on the 
accumulation of genetic abnormalities in the originating cancer cells, but also on the local 
microenvironment that can provide a permissive niche for the survival, growth, and 
migration of the cancer cells (Barcellos-Hoff et al., 2013) (Figure 2). The host 
microenvironment undergoes extensive change during the evolution and progression of 
cancer, so that it is becoming evident that its characterization can provide important 
prognostic and predictive information about tumours, independent of the tumour cell 
phenotype (McAllister and Weinberg, 2014). 
 
 
 
 
 
 
 
 
 
Figure 2. The tumour microenvironment. The tumour microenvironment comprises the cancer cells, and 
either with invasive or staminal phenotype. In addition, endothelial cells, pericytes, fibroblasts, stromal cells 
as well as various immune inflammatory cells contribute to the malignant outgrowth (Figures adapted from 
Joyce and Pollard, Nat Rev Cancer, 2009; 9:239–252). 
 
 
1.2.1    Influence of cancer-associated fibroblasts on tumour behaviour 
Cancer-Associated Fibroblasts (CAFs) are among the most abundant cell type 
in the microenvironment of solid tumours. CAFs form a heterogeneous population, 
probably related to their diverse origin. Whilst activation of local stromal fibroblasts has 
traditionally been considered the major source of CAFs (Kalluri and Zeisberg, 2006), 
experimental models using genetically marked Bone Marrow-Derived Cells (BMDCs) 
have demonstrated that these cells can contribute to the tumour-associated stroma and 
develop markers and functions of CAFs. It has also been suggested that CAFs may be 
derived from normal or tumour cells that undergo Epithelial–Mesenchymal Transition 
(EMT), a theory that may explain the identification of identical genetic alterations in 
tumour epithelium and its associated stroma (Allen and Jones, 2011). 
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There are abundant evidences reporting that CAFs are able to release classical growth 
factors, such as Epidermal Growth Factor (EGF), Transforming Growth Factor Beta 
(TGFβ) and Hepatocyte Growth Factor (HGF), as well as a range of chemokines shown to 
influence different aspects of tumour cell behaviour. Moreover, CAFs directly promote 
tumour growth and mediate the recruitment of endothelial progenitor cells into the tumour 
mass, leading to enhanced angiogenesis (Kalluri and Zeisberg, 2006). Orimo et al. found 
that several unique characteristics of CAFs are maintained even in the absence of contact 
with tumour cells, implying that CAF function is not merely a response to tumour-derived 
signals (Orimo et al., 2005). In addition to promoting growth of established tumours, there 
is strong evidence that altered fibroblast signalling may be critical in the initiation of 
carcinogenesis, in regulating its phenotype and in mediating metastatic spread of tumours 
(Allen and Jones, 2011). Cunha et al. reported that the pro-tumour function of CAFs does 
not simply relate to enhanced mitogenesis. They showed that CAFs does not stimulate 
tumour development in a non-immortalized benign epithelium, suggesting that some 
epithelial abnormality is necessary to respond to the pro-tumourigenic effects of CAFs 
(Olumi et al., 1999). Erez et al. also demonstrated that CAFs support tumourigenesis by 
mediating tumour-enhancing inflammation through a NF-kB–dependent activation of a 
pro-inflammatory gene expression signature (Erez et al., 2010). A recent study by 
Vermeulen et al. has highlighted the role for CAFs also in the regulation of tumour 
behaviour, that of modulating the Cancer Stem Cell (CSC) phenotype (Vermeulen et al., 
2010). This study indicates that the stem cell phenotype is plastic and is dependent on the 
tumour microenvironment, suggesting that targeting the CSC-microenvironment interface 
may be an effective approach to overcome stem cell resistance to current therapies. 
 
1.2.2    Extracellular matrix remodelling in cancer 
Besides releasing a range of chemokines and growth factors, CAFs also 
generate an altered extracellular matrix (ECM) environment. Most solid tumours exhibit a 
very different profile of ECM proteins in the stroma compared to their normal 
counterparts, and many of these proteins interact directly with tumour cells, via integrins 
and other cell surface receptors, to influence functions such as proliferation, apoptosis, 
migration and differentiation (Lu et al., 2012) (Figure 3). 
Among the number of proteins consistently up-regulated in solid tumours, fibronectin (FN) 
has attracted interest in cancer research, owing to its role in tumour progression. FN, a 
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class of high-molecular-weight adhesive glycoproteins, plays a prominent role in 
mediating ECM function, because of its high abundance and its interaction with cellular 
components (Kaspar et al., 2006). In tumours, alternative splicing of FN pre-mRNA, as 
well as post-translational modification, give rise to several isoforms of this complex 
protein. The oncofoetal form of FN that contain the extra-domain (ED)A is known to be 
required for the transduction of TGFβ signals, and the conversion of fibroblasts to 
myofibroblasts, a key event in the tumour microenvironment, whereas the variant that 
contain the extra-domain (ED)B is particularly associated with neovascular structures in 
many different tumour types (Allen and Jones, 2011). 
As well as the composition of the ECM, the mechanical properties of the stroma also have 
a profound impact on function. The tensile strength or stiffness of the ECM can regulate 
epithelial cell growth, differentiation and migration, and reduction of ECM stiffness can 
repress the malignant behaviour the epithelial cells. These stromal changes are mainly 
associated with increased focal adhesion formation and increased Focal Adhesion Kinase 
(FAK) activity, and inhibition of β1-integrin in this context has been shown to prevent 
tumour invasion, suggesting that changes in ECM stiffness regulate epithelial cells through 
integrin signalling (Levental et al., 2009). 
The ECM undergoes significant remodelling during tumour progressions, and this is 
mediated largely by the extracellular proteinases, particularly the matrix 
metalloproteinases (MMPs), and the major source of these are stromal cells (Egeblad and 
Werb, 2002). MMPs are implicated in the promotion of tumour invasion and metastasis. 
By contrast, several recent evidences in literature have shown that some MMPs act as 
tumour suppressors rather than tumour promoters and, as well as inducing angiogenesis, 
may in some instances lead to the activation of anti-angiogenic mechanisms (Deryugina 
and Quigley, 2010). 
 
1.2.3    Tumour angiogenesis and hypoxia  
Angiogenesis, the creation of new vessels from pre-existing ones, is a key 
mechanism of carcinogenesis that is directly related to the aggressiveness of cancer 
(Carmeliet, 2005) (Figure 3). Angiogenesis is required if a tumour is to progress past a 
certain size, and the microenvironment plays an important role in dictating when the 
“angiogenic switch” will occur. This event separates cancer development from small 
lesions, which are dormant, to an exponential growth phase. Tumours, as well as normal 
tissues, require a supply of nutrients and the removal of waste products to survive and 
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proliferate. As tumours grow, areas of nutrient deprivation and hypoxia arise because of an 
insufficient blood supply. 
Although a limiting factor for tumour growth, oxygen deprivation also represents a 
stimulus for invasion and metastasis. A number of studies have shown that hypoxia is 
negative prognostic and predictive factor in cancer, owing to its multiple contributions to 
chemoresistance, radioresistance, angiogenesis, vasculogenesis, resistance to cell death, 
altered metabolism and genomic instability (Wilson and Hay, 2011). Hypoxia stimulates 
Hypoxia-Inducible Family (HIF) of proteins, which regulate diverse cellular processes, 
including metabolism, angiogenesis, cell proliferation, apoptosis and tissue remodelling 
(Carmeliet, 2005). In addition, hypoxia can down-regulate epithelial E-cadherin, thus 
promoting EMT (Esteban et al., 2006) and activate Wnt/β-catenin signalling pathway, 
promoting a more motile and invasive phenotype (Sahlgren et al., 2008); moreover, low 
oxygen tension causes cancer cells to switch to anaerobic metabolism, which greatly 
increases the genetic instability of the cells (Kim et al., 2006). One of the key roles of HIF-
1α in hypoxia is the induction of pro-angiogenic factors, including Vascular Endothelial 
Growth Factor (VEGF), angiopoietin-2, Platelet-Derived Growth Factor (PDGF) and 
Fibroblast Growth Factor (FGF), as well as downregulation of anti-angiogenic factors, 
such as thrombospondin. Whereas the major focus on hypoxia has been its role in 
enhancing angiogenesis, a number of angiogenesis-independent mechanisms for hypoxia-
induced tumour progression have already been described (Fraisl et al., 2009). In one key 
study, Pennacchietti et al. showed that HIF-1α binds to the Hepatocyte Growth Factor 
Receptor (HGFR) promoter, also called c-Met, leading to an “invasive switch” in the 
tumour cells, increasing degradation of the ECM and allowing tumour cells to move freely 
towards more oxygen-rich areas (Pennacchietti et al., 2003). This has therapeutic 
implications, since targeting angiogenesis alone may not be sufficient, and indeed may 
even aggravate this invasive response to hypoxia (Allen and Jones, 2011). 
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Figure 3. The tumour microenvironment continually changes and evolves as the tumour grows, 
creating localized pockets of hypoxia, inflammation and ECM turnover that affect blood vessel growth, 
remodelling and maturation. Environmental or genetic events transform normal epithelial cells into tumour 
cells, which grow and divide with little effect on their surroundings until their size exceeds 1–2 mm. At that 
point, hypoxia and nutrient deprivation trigger the requirement for angiogenesis. Tumour cells release soluble 
growth factors, chemokines and cytokines, which create a concentration gradient that initiates the sprouting 
and proliferation of formerly quiescent endothelial cells on nearby blood vessels and lymphatics. These 
signals also recruit fibroblasts that deposit a repertoire of ECM proteins and enzymes in an attempt to 
remodel and repair the site. Most tumours elicit an inflammatory response that attracts myeloid cells into the 
tumour microenvironment, and these cell types release their stores of soluble factors to escalate the 
angiogenic response, thus favouring tumour progression (Figure from Weis and Cheresh, Nat Med, 2011; 
17:1359–1370).  
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Chapter 2 
 
2.1    Immune system: a double-edged sword in cancer 
Inflammation is a complex physiological process that normally functions to 
maintain tissue homeostasis in response to tissue stressors such as infection or tissue 
damage, and it has recently been proposed to be the seventh hallmark of cancer (Colotta et 
al., 2009). The inflammatory response consists of an innate system of cellular and humoral 
responses following injury, in which the body attempts to restore the tissue to its pre-injury 
state. In the acute inflammatory response, there is a complex orchestration of events, 
involving activation of many different types of cells, such as endothelial and stromal cells, 
as well as activation of platelets and complement system, and recruitment of leukocytes, all 
of which may assist in coping with the state of injury. Acute inflammation frequently 
precedes the development of protective adaptive immune responses to pathogens and 
cancer. On the other hand, long-term inflammatory processes, directed at a particular 
endogenous or exogenous antigen, define the chronic inflammatory response. Chronic 
inflammation contributes to tumourigenesis at all stages. It takes part to cancer initiation by 
generating genotoxic stress, to cancer promotion by inducing cellular proliferation, and to 
cancer progression by enhancing angiogenesis and tissue invasion (Grivennikov et al., 
2010). On the basis of these observations, it has been proposed that tumour-promoting 
inflammation and protective tumour immunity are dynamically interconnected processes 
that vie for dominance as tumour cells develop and transit through cancer immunoediting 
(Schreiber et al., 2011). 
 
2.2    Cancer immunoediting: from immunosurveillance to immune escape 
The immune system plays a dual role in cancer (Hagerling et al., 2014). It can 
not only suppress tumour growth, by destroying cancer cells or inhibiting their outgrowth, 
but also promote tumour progression, either by selecting for tumour cells that are more fit 
to survive in an immunocompetent host or by establishing conditions within the tumour 
microenvironment that facilitate tumour outgrowth (Schreiber et al., 2011). There is a 
growing consensus that the relationship between the immune system and cancer has more 
dimensions than just immunosurveillance (Dunn et al., 2002; Schreiber et al., 2011). Apart 
from eliminating cancer cells, immunity also sculpts the immunogenic phenotype of 
tumours to evade immune control. Analogous to Darwinian evolution, the immune system 
exerts selection pressure on the rapidly mutating, heterogeneous and genetically unstable 
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tumour mass to develop variants with reduced immunogenicity, to escape immunologic 
detection and destruction. These dual effects of the immune system on developing tumours 
prompted a refinement of the cancer immunosurveillance concept into the one termed 
cancer immunoediting (CI). This is a dynamic process composed of three phases: 
elimination, also known as immunosurveillance or protection, equilibrium or persistence, 
and escape or progression, which are collectively denoted the “three Es” of CI (Figure 4). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The “three Es” of cancer immunoediting. Cancer immunoediting (CI) is an extrinsic tumour 
suppressor mechanism that engages only after cellular transformation has occurred and intrinsic tumour 
suppressor mechanisms have failed. CI consists of three sequential phases: elimination, equilibrium and 
evasion. In the elimination phase, transformed cells are detected by the innate and adaptive immune system 
sensing stress signals, Natural Killer-Receptor (NKR) ligands and the presence of Tumour-Associated 
Antigens (TAAs). This leads to elimination of the nascent tumour, before it reaches clinically apparent stages. 
In the equilibrium phase, tumour cells that were not deleted are merely hold in check by the immune system. 
The genetically unstable tumour mass is being selected to develop less immunogenic variants and induce an 
immunosuppressive tumour promoting microenvironment. Just like the elimination phase, the equilibrium 
phase is clinically not apparent and can last many years. In the evasion phase, the tumour has evolved into a 
non-immunogenic, highly immunosuppressive malignancy that attracts various innate and adaptive immune 
cells fostering invasive growth and maintaining a permissive environment while suppressing effector T-cell 
and CTL function (Figure from Schreiber et al., Science, 2011; 331:1565–1570). 
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2.2.1    Elimination phase: anti-tumour immune response  
The elimination phase of CI is an updated version of the original concept of 
cancer immunosurveillance, in which the innate and adaptive immune systems work 
together to detect the presence of a developing tumour and destroy it before it becomes 
clinically apparent. In the case of partial tumour elimination, the theory of immunoediting 
is that a temporary state of dynamic equilibrium can then develop between the immune 
system and the developing tumour (Schreiber et al., 2011). The elimination phase has only 
been observed indirectly in vivo, but its existence has been inferred from the earlier onset 
or greater penetrance of neoplasia in immunodeficient mice (Vesely et al., 2011).  
The initiation of the anti-tumour immune response occurs when cells of the innate immune 
system become alerted of the presence of the growing tumour, although the mechanisms of 
their activation are not yet completely understood. Local tissue disruption, as a result of 
increased angiogenesis, hypoxia, genome instability or tissue-invasive growth, and release 
of antigens during tumour cell necrosis, as well as oncogene-induced expression of stress-
ligands, induces proinflammatory molecules, such as Interleukin 1 and 15 (IL-1; IL-15), 
Tumour Necrosis Factor α (TNFα), Granulocyte-Macrophage Colony-Stimulating Factor 
(GM-CSF), leading to the recruitment of innate immune cells. Dendritic cells may act as 
sentinel cells sensing tissue stress, damage and transformation. Their ability to uptake heat 
shock proteins and products of ECM breakdown promotes differentiation and subsequent 
crosstalk between Dendritic Cells (DCs) and Natural Killer cells (NK-cells). These cells, 
as well as Macrophages (MФ), gamma delta T-cells (γδ T-cells) and Natural Killer T-cells 
(NKT-cells) are among the first cells attracted by cancerous lesions and comprise the first 
line of defence against tumours. They are recruited to the site of “danger” and recognize 
molecules that can be induced on tumour cells upon cellular transformation, such as stress 
induced ligands for the activating Natural-Killer Group 2, member D receptor (NKG2D) 
(Smyth et al., 2005). In addition, either Major Histocompatibility Complex (MHC)-tumour-
associated peptide or glycolipid-CD1 complexes expressed on developing tumour cells can 
be recognized by T-cells and NKT-cells, respectively (Smyth et al., 2002). These immune 
cells exert several effector mechanisms to eliminate tumour cells including the release of 
Interferon-γ (IFN-γ) and perforin, or the expression of death receptor ligands, such as the 
TNF-Related Apoptosis-Inducing Ligand (TRAIL). Secretion of IFN-γ controls tumour 
growth and amplifies immune responses through the production of chemokines. In return, 
chemokines attract more immune cells to the tumour site generating a positive feedback 
loop for tumour elimination. In the next phase, tumour antigens released, during tumour 
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cell killing, drive the development of tumour-specific adaptive immune responses. 
Recruited immature DCs become activated through the tumour cytokine milieu and uptake 
of tumour antigens and migrate to the lymph nodes, where they induce the activation of 
naïve tumour-specific CD4+ and CD8+ T-cells (Griffith et al., 2014). Once activated, 
tumour-specific T-cells home to the tumour site to eliminate antigen-expressing tumour 
cells. 
 
2.2.2    Equilibrium phase: tumour persistence 
In the equilibrium phase immune cells and tumour cells, which survived the 
elimination phase, enter a dynamic process where new tumour variants with increased 
resistance to the immune attack arise (Aguirre-Ghiso, 2007). Schreiber and colleagues 
hypothesized that this immune-mediated latency phase is characterized by tumour 
dormancy and may be the longest one, occurring over a period of many years in humans 
(Smyth et al., 2006). Moreover, Koebel et al. showed that, unlike in the elimination phase, 
only the adaptive immune system plays a crucial role in the equilibrium phase (Koebel et 
al., 2007). During this period, heterogeneity and genetic instability of remaining cancer 
cells may favour the generation of poorly recognized tumours by the immune system, that 
have acquired mechanisms that suppress immune effector functions. 
 
2.2.3    Evasion phase: tumour progression  
The escape phase of CI is always clinically apparent, since it leads to a rapid 
progression of tumours. It is characterized by the presence of tumour variants that evade 
immune detection, are resistant to immune-mediated killing and that are able to induce an 
immunosuppressive microenvironment tolerating or even fostering tumour growth 
(Schreiber et al., 2011). Overcoming immunosurveillance by escape is one of the 
hallmarks of cancer (Colotta et al., 2009; Hanahan and Weinberg, 2011). Tumour cell 
evasion can occur through the development of intrinsic mechanisms at the cancer cell 
level; alternatively, escape may result from the establishment of an immunosuppressive 
state within the tumour microenvironment (Schreiber et al., 2011). 
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2.2.3.1    Tumour cell intrinsic mechanisms 
A number of alterations in the tumour cell itself can reduce the chance of 
detection and destruction by the immune system. Selected tumour cell variants may avoid 
immune recognition by interfering with antigen presentation via down-regulation or loss of 
MHC class I protein expression, blocking the antigen processing and loading machinery 
(Khong and Restifo, 2002) or by becoming insensitive to IFN-γ (Dunn et al., 2005). 
Moreover, since the immune system negatively selects against specific tumour antigens, 
variants not expressing these antigens will prevail (Schreiber et al., 2011). In a similar 
fashion, cells may lose the expression of ligands for activating NK-cell receptors, such as 
NKG2D to escape detection of the innate immune system (Spear et al., 2013). Another 
important cell intrinsic alteration is the resistance to apoptosis, a classical hallmark of 
cancer (Hanahan and Weinberg, 2011). Anti-apoptotic members of the B-cell lymphoma 2 
(Bcl-2) family, the expression of mutated inactive death receptors, such as Fas, and the 
persistent activation of pro-oncogenic transcription factors, such as Signal Transducer and 
Activator of Transcription 3 (STAT3) (Schreiber et al., 2011) are frequently found in 
progressively growing tumours. In addition to being resistant to extrinsic induction of 
apoptosis, expression of inhibitory ligands such as Programmed Death Ligand-1 (PD-L1) 
may directly dampen cytotoxicity of T-cells and even induce apoptosis of cancer cells. 
Further evidences also reported that a direct “counterattack” by expression of Fas-ligand 
on tumour cells induces apoptosis in Fas-expressing T-cells (Vesely et al., 2011). 
 
2.2.3.2    Establishment of an immunosuppressive environment 
Beyond cell intrinsic mechanisms and alterations involving direct juxtacrine 
signalling, tumours establish a local immunosuppressive environment that prevents a 
protective anti-tumour response despite systemic immunocompetence (Schreiber et al., 
2011). Tumour-derived immunosuppression is achieved by secretion of 
immunosuppressive soluble mediators. These molecules include VEGF, that leads to 
increased angiogenesis to overcome shortage of oxygen and nutrient supply, TGFβ, which 
suppresses effector NK-cells, DCs and T-cells, whereas it takes part into the differentiation 
of regulatory T-cells (Treg) cells and Th-17 cells, as well as indoleamine 2,3-dioxygenase 
(IDO) and interleukin (IL)-10, able to inhibit T-cells (Vesely et al., 2011). Furthermore, 
soluble factors that inhibit the activation of the innate immune system include decoy 
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ligands for NKG2D, that are shed from the cell membrane and thus interfere with innate 
recognition of transformed cells (Spear et al., 2013). 
Apart from blocking effector function of infiltrating immune cells, progressing tumours 
often attract regulatory and suppressive immune cells, that in turn suppress anti-tumour 
responses (Vesely et al., 2011). Treg cells and Myeloid-Derived Suppressor Cells 
(MDSCs) are two major types of immunosuppressive leukocyte populations that play key 
roles in inhibiting host-protective anti-tumour responses. Treg cells are CD4+ T-cells, 
which constitutively express Interleukin-2 Receptor Alpha chain (IL2RA; CD25) and the 
Forkhead box P3 transcription factor (FoxP3). Treg cells are able to inhibit the function of 
cytotoxic T lymphocytes (CTL; CD8+ T-cells). This occurs either by producing the 
immunosuppressive cytokines IL-10 and TGF-β or by expressing the negative co-
stimulatory molecules Cytotoxic T-Lymphocyte-Associated protein 4 (CTLA-4; CD152), 
Programmed cell Death protein 1 (PD-1; CD279), and PD-L1 and by consuming IL-2, a 
cytokine that is critical for maintaining CTL function (Schreiber et al., 2011). 
Various tumour-derived soluble mediators, including VEGF, IL-1β and Prostaglandin-E2 
(PGE2) also attract a heterogeneous group of immature myeloid cells and myeloid 
progenitor cells collectively termed MDSCs (Khaled et al., 2013). MDCSs directly inhibit 
lymphocyte function, by inducing Treg cells, secrete a number of immunosuppressive 
molecules, including IL-10 and TGF-β, as well as sequester the amino acids arginine, 
tryptophan, and cysteine required for T-cell function, or nitrating T-cell receptors or 
chemokine receptors on tumour-specific T-cells (Schreiber et al., 2011). 
Tumour-associated macrophages (TAMs) are another myeloid cell type that contribute to 
the immunosuppressive microenvironment of the tumour. Attracted by IL-4 and IL-13, 
TAMs are usually M2-polarized macrophages and mediate suppression by secretion of 
TGF-β and IL-10 (Noy and Pollard, 2014). 
Taken together, the escape phase of cancer immunoediting involves various cell types of 
both adaptive and innate immunity, a fundamental change in the prevalent signalling 
molecules, and is not only dependent on various types of cells attracted to the tumour, but 
also on repolarization of inflammatory cells that already present surrounding the tumour. 
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Chapter 3 
 
3.1    The Complement System  
Complement (C) is a well-known arm of innate immunity, providing an early 
warning signal and fast response upon encountering a foreign antigen, although recent 
findings have revealed that C orchestrates many more immunological and inflammatory 
processes that contribute to maintain the homeostasis of different organs and tissues 
(Ricklin et al., 2010). The C system is populated by more than 50 proteins found in the 
fluid phase and on cell surfaces, which function as a proteolytic cascade amplifying an 
initial signal (Walport, 2001; Pio et al., 2014). These proteins can be zymogens, which 
become active enzymes upon activation of C, effectors, receptors, or control proteins, 
which help maintain well-balanced activation and inhibition of the system. The role that C 
plays in immunity is multifaceted and complex. It functions in infection control through 
cytolysis of invading pathogens, opsonisation for phagocytosis and release of 
anaphylatoxins, which recruit and activate immune cells. It is also important in immune 
complex clearance. C can act as a bridge between innate and adaptive immunity helping to 
regulate B- and T-cell responses. Apart from these key immune functions, it is implicated 
in processes including regulation during development of neuronal networks, tissue 
regeneration and angiogenesis (Pio et al., 2014). 
 
3.1.1    Pathways of complement activation 
The C system has three well-established activation pathways, classical, lectin and 
alternative (Walport, 2001) (Figure 5). 
The first component of the classical pathway is C1 (C1qr2s2) complex, which is formed by 
C1q together with C1r and C1s, two serine protease proenzymes (Kojouharova et al., 
2010). Activation of this pathway is primarily initiated by the binding of C1q to either IgG 
or IgM bound to antigen in immune complexes (Degn and Thiel, 2013). This pathway can 
also be activated in the absence of antibodies, following the recognition by C1q of several 
endogenous ligands, including dying cells (Nauta et al., 2002), ECM proteins (Sjöberg et 
al., 2009) and the fluid phase pattern recognition molecule pentraxin 3 (PTX3) (Doni et al., 
2012), as well as the acute-phase protein C-reactive (PCR) protein (McGrath et al., 2006). 
Binding of C1q induce a conformational change leading to auto-activation of the 
associated C1r, which then cleaves and activates C1s (Venkatraman Girija et al., 2013). 
Thus, C1s can cleave both the C proteins C4, to release the anaphylatoxin C4a, and the 
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C4b fragment, and C2, to produce C2a and C2b fragments, which forms part of classical 
C3-convertase (C4b2a), in conjunction with C2a. The resulting C3 convertase is 
responsible for the initiation of the common terminal pathway (Degn and Thiel, 2013). 
The lectin pathway is initiated upon binding of mannose-binding lectin (MBL) or one of 
the ficolins (M, L and H) to patterns of N-acetyl residues and those of carbohydrate 
surfaces. MBL and ficolins are soluble pattern-recognition molecules, that share with C1q 
collagen-like regions (Degn and Thiel, 2013). These proteins form a C1q-like complex 
with MBL-Associated Serine Proteases (MASPs), cleaving the C components C4 and C2 
to form the C3-convertase, which is common to the classical pathway activation route 
(Fujita, 2002). 
The alternative pathway could be activated by spontaneous low-level hydrolysis of the 
central component of the C system, C3, to form C3(H2O). This mechanism of activation is 
referred to be as the “tick-over” of C3. C3(H2O) can bind to factor B, which is cleaved by 
factor D to form the initial alternative pathway C3-convertase, C3(H2O)Bb. Kinin-
generating proteases kallikrein and thrombin are also capable of activating C (Kolev et al., 
2014) by cleaving C3. 
All C pathways converge on the C3 molecule, which upon cleavage by the C3-convertase 
(C4b2a) forms C3a, a potent anaphylatoxin, and C3b, an opsonin (Walport, 2001; Kolev et 
al., 2014). C activation is tightly regulated in vivo, so that various regulators rapidly cleave 
C3b to its inactive form, iC3b. However, some C3b can bind to C-activating surfaces and 
associate with factor B, and this protein complex again can be cleaved by factor D, 
forming the predominant alternative pathway C3-convertase (C3bBb). The binding of 
properdin enhance the stability of this convertase. C3bBb can also generate large amounts 
of C3b through the alternative pathway amplification loop. Binding of another C3b-
fragment to the C3-convertase creates a C5 convertase, which consists of C3b3bBb in the 
alternative pathway, instead of C4b2a3b to the classical or lectin pathway. C5 convertase 
can cleave the C protein C5 to release C5a, another potent anaphylatoxin of the C system, 
and C5b, that associates with C6 and C7 to form C5b67 complex, which inserts into the 
cell membrane and then binds to C8 and C9 to form the membrane attack complex (MAC), 
also known as C5b-9 complex. The latter, also known as Terminal Complement Complex 
(TCC) promotes lysis of cells and microorganisms when in sufficient quantities (Walport, 
2001; Kolev et al., 2011). 
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Figure 5. Cascade of events during the activation of the complement system. C activation represents a 
well-preserved innate immune response, which is able to act fast, within seconds to minutes, as well as 
sustainable (over days). The activation of the C system can occur through at least three well-known 
pathways: the classical, the lectin and the alternative pathway. 
Activated C1q, in complex with C1s and C1r, initiates the classical pathway upon binding of antigen-
antibody complexes. The lectin pathway starts upon recognition of certain oligosaccharide moieties by 
Mannose/Mannan Binding Lectin (MBL) or ficolins, in complex with Mannan-binding lectin-Associated 
Serine Protease (MASPs). The alternative pathway can be activated either by the presence of foreign 
surfaces, such as lipopolysaccharides (LPS), or through C3(H2O), generated by spontaneous hydrolyses, the 
so-called “tick-over” mechanism. 
All three pathways merge at the level of C3. Through the formation of C3 convertases (C4b2a for the 
classical and lectin pathways, and C3bBb or C3(H2O)Bb for the alternative pathway), these pathways 
culminate in the generation of the opsonin C3b, and the anaphylatoxin C3a. Subsequent C5 convertase 
formation (C4b2aC3b for the classical and lectin pathways, and C3bBbC3b for the alternative pathway) leads 
to C5b and anaphylatoxin C5a generation, C5b is then able to bind C6 and be released from the surface. 
C5b6 once bound to C7 and C8 begins to deposit and allow C9 polymerisation, to form the Membrane Attack 
Complex (MAC) and its insertion into target membranes. 
Self-tissue is protected from C deposition through fluid-phase and cell-bound regulators. C1-inhibitor (C1‑
INH) is an esterase that irreversibly bind to and inactivate C1r, C1s, MASP-1 and MASP-2 proteases, thus 
preventing the proteolytic cleavage of later C components C4 and C2 by C1 and MBL. Convertases are 
regulated through disassembly by several regulators, such as the serine protease C Factor I (FI) as well as 
one of several cofactor proteins, such as surface-bound CD46 and the decay-accelerating factors CD55 and 
CD35, also known as C receptor type 1 (CR1), or fluid-phase Factor H (FH) and C4b-binding protein 
(C4BP). The formation of the MAC is controlled by CD59, which can prevent the polymerization of C9, and 
vitronectin, a multifunctional glycoprotein able to block the binding of C5b-7 on the cell membrane and to 
prevent the C9 polymerization (Adapted from Kolev, Friec and Kemper, Nat Rev Immunol, 2014; 14, 811–
820. Figure modified from Pio, Ajona and Lambris, Semin Immunol, 2013; 25:54-64). 
VITRONECTIN 
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3.2    The role of complement in tumour growth 
 
3.2.1    Immune surveillance function of complement in cancer 
The C system is one of the immune actors present in the tumour 
microenvironment and plays an important role in the control of tumour growth (Macor and 
Tedesco, 2007; Pio et al., 2014). The numerous genetic and epigenetic alterations 
associated with carcinogenesis dramatically change the morphology and composition of 
the cell membrane. Altered glycosylation is considered a hallmark of cancer cells 
(Hanahan and Weinberg, 2011; Christiansen et al., 2014), and progression of epithelial 
cells from a normal to malignant phenotype is associated with an aberrant increase in the 
metabolism of membrane phospholipids (Glunde et al., 2011). Cancer-related membrane 
modifications can be recognized by innate and adaptive immune mechanisms that protect 
the host against the development of cancer (Pardoll, 2003). Several studies of many 
different types of solid and hematopoietic cancer have suggested that the C system is 
activated in response to the expression of tumour-associated antigens, with the subsequent 
deposition of C components on tumour tissue (Markiewski and Lambris, 2009a; Pio et al., 
2014). The exact trigger for C activation upon transformation is still not fully understood, 
although activation through immune complexes, antibody binding or direct C1q binding to 
necrotic and apoptotic cellular components are all possibilities. The relative contribution of 
each activation pathway has not yet been clarified, but increasingly data suggest an 
influence of all three pathways (Pio et al., 2013, 2014).  
Some of the first evidence for the classical pathway of C activation by malignant 
transformed cells was revealed by immunohistochemical analysis of breast cancer tissue, 
which showed deposition of the MAC and the C components C4 and C3, in contrast to the 
lack of such components in adjacent benign breast tissue (Niculescu et al., 1992). In vitro 
studies have shown spontaneous activation of the classical C pathway by two 
neuroblastoma cell lines (Gasque et al., 1996). Evidence for activation of this pathway has 
been found also in patients with papillary thyroid carcinoma (Yamakawa et al., 1994; 
Lucas et al., 1996), on which deposits of MAC, C3d, C4d, C5, IgG1 and IgG4 were 
detected, as well as in patients with follicular lymphoma, and mucosa-associated lymphoid 
tissue lymphoma (Bu et al., 2007). In vivo alterations in the activation of the classical 
pathway have been described in patients with chronic lymphatic leukaemia (Schlesinger et 
al., 1996), with a strong positive correlation between survival and the initial activity this 
pathway of complement (Varga et al., 1995). Recently, Markiewski et al. demonstrated 
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that the classical pathway is the main contributor to C activation in a syngeneic mouse 
model of cervical cancer (Markiewski et al., 2008). 
The lectin pathway of C activation has been found to be significantly increased in patients 
with colorectal cancer (Ytting et al., 2004) and pancreatic cancer (Rong et al., 2010) when 
compared to healthy subjects, suggesting MBL may be activated in response to malignant 
transformation. Swierzko et al. recently reviewed that MBL may play various roles in 
malignancy, depending on the type of cancer, age or ethnicity of patients, as well as mode 
of treatment (Swierzko et al., 2013). The concentration of MASP-2 in serum has also been 
reported to be an independent prognostic marker for poor survival (Ytting et al., 2005). 
The alternative C pathway has been found to be activated in lymphoblastoid cell lines 
(Theofilopoulos and Perrin, 1976; McConnell et al., 1978) and in patients with multiple 
myeloma (Kraut and Sagone, 1981). In childhood acute lymphoblastic leukaemia, 
amplification of the alternative pathway after activation of the classical pathway has also 
been suggested (Kalwinsky et al., 1976). The presence of elevated levels of C3a and 
soluble MAC in the intraperitoneal ascitic fluid of patients with ovarian cancer also 
indicates activation of the alternative and classical pathways in this tumour type, supported 
by the deposition of some activation products, such as C3d and C1q, on the surface of 
tumour cells (Bjørge et al., 2005). 
Recently, C activation has also been observed in in vitro studies of cancer cell lines, in the 
absence of an exogenous source of C components (Pio et al., 2014). Lung tumour cells 
deposit C5 and generate the active product C5a more efficiently than non-malignant 
bronchial epithelial cells (Corrales et al., 2012), although the antigens responsible for this 
activation and the pathways involved are not known yet. Moreover, a significant increase 
in C5a was found in the plasma samples of patients with NSCLC, suggesting that the local 
generation of C5a within tumours may be followed by its systemic diffusion (Corrales et 
al., 2012). Recently, Cho et al have also identified a prominent role for tumour-derived C 
production and activation in ovarian cancer growth and progression (Cho et al., 2014). 
Ovarian cancer cells have been shown to secrete C3 in the tumour mass, and the 
production of C3a has confirmed that C proteins, involved in the C activation inside the 
tumour, are originated locally (Cho et al., 2014). These evidences suggest that, apart from 
the traditional pathways of C activation, cancer cells may have the capacity to activate C 
by extrinsic activation mechanisms (Corrales et al., 2012). The production of 
anaphylatoxins by cancer cells has been recently reported to be mediated, at least in part, 
by soluble and membrane-bound proteases, such as serine proteases of the coagulation and 
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fibrinolysis systems or cell-bound proteases (Huber-Lang et al., 2002, 2006; Amara et al., 
2008). 
 
3.2.2    Complement and immunotherapeutic monoclonal antibodies in cancer 
The involvement of C in cancer immunosurveillance has long been neglected 
until monoclonal antibodies (mAbs) were introduced in cancer therapy (Scott et al., 2012). 
mAbs target tumour-specific and Tumour-Associated Antigens (TAA) and block important 
cancer activities. In addition, many of them are able to activate the immune system and 
mediate Fc domain–based reactions by Antibody-Dependent Cellular Cytotoxicity (ADCC) 
(Kolev et al., 2011). Besides mediating ADCC, some mAbs trigger C activation by C-
Dependent Cytotoxicity (CDC) and C-Dependent Cellular Cytotoxicity (CDCC) 
(Markiewski and Lambris, 2009b; Meyer et al., 2014), that helps to control tumour growth 
by a direct cytotoxic effect on cancer cells and by promoting inflammation (Taylor and 
Lindorfer, 2014a). The advantage of the C system over ADCC is that it is made of soluble 
components readily available at tissue site, where they are secreted by various cell types 
recruited from the circulation as a result of the inflammatory process and sometime also by 
the tumour cells (Macor and Tedesco, 2007). Successful C activation by these therapeutic 
antibodies can also have other effects on the immune response against tumours, such as the 
formation of the MAC, opsonization, and release of proinflammatory anaphylatoxins (Pio 
et al., 2014). 
The number of mAbs approved for cancer treatment has rapidly increased since the anti-
CD20 rituximab was first used for the treatment of malignant lymphomas (Table 1). 
Rituximab exerts its effects through a variety of mechanisms, including CDC, although its 
efficacy has been reported to be limited by the expression of CRPs in B-cell lymphoma 
cell lines (Taylor and Lindorfer, 2014b). Several studies are underway to enhance 
anticancer efficacy of mAbs by overcoming the resistance to C-activation exerted by 
CRPs. 
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Table 1. Therapeutic monoclonal antibodies approved or in review in the European Union or the 
United States for use in cancer treatment. (#, Withdrawn; NA, Not Approved; Rev, In Review; P, pending; 
EC, European Community; Mu, Murine; Hu, Human; Hum, Humanized; Chi, Chimeric; Bis, Bispecific. 
Tumour types: NSCLC, Non-small cell lung cancer; ALL, Acute lymphoblastic leukaemia; CLL, Chronic 
lymphocytic leukaemia; ALCL, anaplastic large cell lymphoma; CML, Chronic myeloid leukaemia; AML, 
Acute myeloid leukaemia. Table adapted from Janice M. Reichert, Reichert Biotechnology Consulting LLC; 
updated November 5th, 2014. http://www.antibodysociety.org/news/approved_mabs.php). 
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3.2.3    Cancer-associated resistance mechanism to complement activation 
The contribution of C to the antibody-mediated cancer cell killing remains 
controversial (Pio et al., 2014). Cancer cells exhibit a number of strategies to resist C 
attack (Jurianz et al., 1999). Many of these resistance mechanisms are used also by normal 
cells to avoid accidental activation or bystander effects from a local activation of C. 
However, cancer cells develop additional mechanisms to inhibit C activation, thus 
promoting tumour growth (Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Mechanisms used by cancer cells to resist complement activation. The efficacy of C-dependent 
cytotoxicity is strongly restricted due to the expression and acquisition of regulators of C activation. Cancer-
resistance associated mechanisms can be divided into two categories: extracellular, which are spontaneously 
expressed in cells without a need for prior activation, whereas the induced intracellular mechanisms develop 
in cells subjected to stimulation with cytokines, hormones, drugs or with sublytic doses of C and other pore-
formers. Membrane-associated C regulatory proteins, such as CD55, CD46, CD35 and CD59, serve as an 
important mechanism of self-protection and render autologous cells insensitive to the action of C. These C 
regulators appear to be overexpressed on several tumours. Furthermore, tumour cells secrete several soluble 
C inhibitors. Tumour cells may also release proteases that degrade C proteins, such as C3; moreover, cancer 
cells may express ecto-protein kinases (ecto-PK), which can phosphorylate C9 protein in the C9a fragment, 
responsible for the interaction of the unfolded C9 with the preformed C5b-8 complex in the formation of the 
MAC. Besides this basal resistance, nucleated cells resist, to some extent, C damage by removing the MAC 
from their surface. Several biochemical pathways, including protein phosphorylation, activation of G-
proteins and turnover of phosphoinositides have been implicated in resistance to C. Calcium ion influx and 
activation of PKC and of MAPK have also been demonstrated to be associated with the C-induced enhanced 
resistance to lysis. Red lines represent inhibitory activity (Adapted from Jurianz et al., Mol Immunol, 1999; 
36:929–939. The figure is from Pio, Corrales and Lambris, Adv Exp Med Biol, 2014; 772:229-62). 
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One of the best characterized cancer-associated resistance mechanism is the expression of 
membrane-bound C Regulatory Proteins (mCRPs), CD46, CD55 and CD59, that are 
overexpressed on tumour cells (Jurianz et al., 1999; Fishelson et al., 2003; Kolev et al., 
2011). 
CD46, also known as Membrane Cofactor Protein (MCP), is a type I membrane regulatory 
protein of the C. It has cofactor activity for inactivation of C components C3b and C4b by 
serum factor I, which protects the host cell from damage by C (Kolev et al., 2011). CD46 
is perhaps the mCRP with the lowest level of variation between tumours and normal tissue. 
Nevertheless, CD46 levels are correlated with tumour grade and recurrence in breast 
tumours (Rushmere et al., 2004; Madjd et al., 2005). 
CD55, also known as C Decay-Accelerating Factor (DAF), is a glycophosphatidyl (GPI)-
anchored protein that interferes with the ability of C4b and C3b to catalyse the conversion 
of C2 and factor B to active C2a and Bb, and thereby prevents the formation of C4b2a and 
C3bBb, thus blocking the formation of the Membrane Attack Complex (MAC) (Kolev et 
al., 2011). Prostatic tumours and medullary thyroid carcinomas were reported to 
overexpress CD55 and its receptor CD97 (Loberg et al., 2006). The correlation between 
the level of CD55 expression in human breast cancers and disease prognosis is still 
unclear: high CD55 expression has been correlated to a higher tumour size and poor 
outcome (Ikeda et al., 2008), while others demonstrated that the loss of CD55 is related to 
poor prognosis (Madjd et al., 2004, 2005). In colorectal carcinoma, the expression of CD55 
has also been shown to be associated with poor prognosis (Durrant et al., 2003). Over-
expression of CD55 in human cervical cancer tissue was shown to correlate with reduced 
deposition of C3b compared to surrounding tissue, suggesting C inhibition is relevant in 
vivo (Gao et al., 2009). 
CD59, also known as MAC-inhibitory protein (MAC-IP), is a GPI-anchored protein able to 
bind the C proteins C8 and/or C9, thereby inhibiting the incorporation of multiple copies of 
C9 during the assembling of the MAC (Kolev et al., 2011). In several cancer types, 
increased levels of CD59 have been found to be associated with resistance to CDC 
(Brasoveanu et al., 1996; Chen et al., 2000; Coral et al., 2000; Jarvis et al., 1997), 
increased metastatic potential (Loberg et al., 2005), or poor prognosis (Xu et al., 2005; 
Watson et al., 2006). A recent study shown also that the expression of CD59 determines 
huge xenograft tumours in a mouse model of ovarian cancer (Shi et al., 2009). More 
recently, Li et al. reported that the suppression of CD59 expression enhanced C-mediated 
apoptosis of lung cancer cells through the induction of Fas (Li et al., 2013). 
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The expression of both these mCRPs was found to correlate to prognosis in Non-Small Cell 
Lung Cancer (NSCLC) and contribute to disease resistance to herceptin, an anti-Her2/neu 
mAb, treatment, whose efficacy relies upon C activation (Zhao et al., 2009). The inhibition 
of CD55 and CD59 has also been shown to sensitise primary Uterine Serous Carcinoma 
(USC) to both CDC and ADCC in vitro and, if specifically targeted to tumour cells, to 
significantly increase trastuzumab-mediated therapeutic effect in vivo (Bellone et al., 
2012). A more recent study has demonstrated that also Head and Neck Squamous Cell 
Carcinoma (HNSCC) massive upregulate all mCRPs on cancer cells and in the 
surrounding tissue, leading to the enhancement of C resistance in the tumour 
microenvironment (Kesselring et al., 2014). 
Overall, the correlation between expression and prognosis of the mCRPs in several human 
carcinomas suggests a key role for C during tumourigenesis, and provide evidences for the 
use of mCRPs as candidate targeting gene in cancer therapy (Geis et al., 2010; Carter and 
Lieber, 2014). 
Several types of cancer cell lines release soluble forms of the mCRPs, and many of these 
factors also have been detected in patients with cancer (Pio et al., 2014). These forms of 
mCRPs, including C Factor H (FH) and its truncated form Factor H-Like protein 1 (FHL-
1), have been extensively reported to bind to tumour cells, contributing to their resistance 
to C activation and CDC (Ajona et al., 2004). 
FH is a soluble glycoprotein that regulates the C activation by possessing both cofactor 
activity for the Factor I (FI) mediated C3b cleavage, and decay accelerating activity against 
the alternative pathway C3-convertase. FH has been shown to regulate the activation of C 
in the SK-MEL-93-2 melanoma cell line (Ollert et al., 1995), while Cheng et al. reported 
that FH is a tumour diagnostic marker for bladder cancer (Cheng et al., 2005). 
Downregulation of FH has also been reported to reduce the growth of lung cancer cells in 
vivo (Ajona et al., 2007), and its expression in lung adenocarcinomas may be associated 
with worse prognosis (Cui et al., 2011). Lung cancer cell lines downregulate the expression 
of FH, FI, CD46, and CD55 under hypoxic conditions and during reoxygenation of tissues, 
implying that, under these conditions, cancer cells reduce their reliance on mechanisms to 
control C activation while keeping free from CDC (Okroj et al., 2009). FH and FHL-1 are 
highly expressed by ovarian carcinomas, both proteins are abundantly present in ascites 
from these tumours (Junnikkala et al., 2002) and are able to promote the inactivation of 
C3b in the H2 glioblastoma cells (Junnikkala et al., 2000). In vitro studies have shown that 
also lung cancer cell lines are more resistant to CDC than human nasal epithelium primary 
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cell cultures thank to the expression and secretion of these two factors to the extracellular 
milieu (Ajona et al., 2004). 
Factor I (FI) is a serine protease capable of degrading the activated C components C3b and 
C4b, whilst C4b-binding protein (C4BP) acts as its cofactor. One of the first evidence of 
the involvement of C4BP in cancer showed that this protein is able to bind to ovarian 
tumour cells and retain its cofactor activity for FI-mediated inactivation of C4b, thus 
increasing the control of classical C pathway activation on the surfaces of cancer cells 
(Holmberg et al., 2001). Recently, Okroj et al. showed that NSCLC cell lines express both 
FI and C4BP, efficiently supporting C inhibition and contributing to the aggressive tumour 
phenotype in vitro (Okroj et al., 2008). This study provides further protection from C 
beyond the level ensured by mCRPs. 
In addition to the expression of mCRP and soluble regulators, there are several alternative 
mechanisms used by cancer cells to control C activation (Pio et al., 2014). Tumour cells 
can either release proteases that cleave C components, or express them in their cell 
membrane. The overexpression of procathepsin-L in DX-3 melanoma cells was reported to 
increase the tumourigenicity of the cells and switch their phenotype from non-metastatic to 
highly metastatic (Frade et al., 1998). Recently, the overexpression of MMP-1 in the 
B16/F1 murine melanoma cells has been shown to protect these cells from the damaging 
effects of C and promote the formation of lung metastasis in vivo (Rozanov et al., 2006). 
More recent evidences showed that the matrix secreted and cell-surface associated 
proteoglycan serglycin protects the survival of myeloma (Skliris et al., 2011) and breast 
(Korpetinou et al., 2013) cancer cells from the attack specifically of the classical and the 
lectin pathways of the C system.  
Tumour cells are able to eliminate the MAC by endocytosis or vesiculation (Moskovich 
and Fishelson, 2007). Interestingly, sublytic doses of the MAC have been shown to provide 
intracellular protection against C attack. Insertion of the MAC into the cell membrane 
causes a variety of biological effects, including entrance into the cell cycle, resistance to 
apoptosis, expression of adhesion molecules, or augmentation of C resistance (Liu et al., 
2012), although the mechanisms responsible for this protection are still under 
investigation. Kraus et al reported that cell desensitization in the chronic myelogenous 
leukemia K562 cancer cell line by sublytic doses of the C5b-9 protein complex involves a 
signalling cascade that includes Protein kinase C (PKC)-mediated extracellular signal-
regulated kinase (ERK) activation (Kraus et al., 2001). Vlaicu and colleagues showed that 
sublytic MACs play a role in tumour cell activation, proliferation and differentiation. 
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These effects have been shown to result in the regulation of cell cycle genes, activated by 
the Phosphatidylinositol 3-Kinase (PI3K)/Akt and ERK1 pathways (Vlaicu et al., 2013). 
Sublytic MACs have also shown to inhibit apoptosis, by inducing the phosphorylation of 
the pro-apoptotic Bcl-2-associated death promoter (Bad) and blocking the activation of 
caspase-8, and the pro-apoptotic protein BH3 interacting-domain death agonist (Bid) 
(Tegla et al., 2011). 
 
3.2.4    Strategies for the improvement of complement-mediated immunotherapy 
The possible role CRPs have in protecting tumours has been of great interest to 
those studying resistance to C fixing antibody in immunotherapy (Meyer et al., 2014). The 
abrogation of inhibitory activity of CRPs has been demonstrated in several in vitro and in 
vivo studies (Kolev et al., 2011), in which CRPs protection is removed, leading to a 
significant increase in tumour cell sensitivity to mAb-based C lysis. Strategies include 
blockade of the activity of the regulators, for example with anti-CD55 and anti-CD59 in 
human mammary (Ellison et al., 2007), ovarian and prostate carcinoma cells (Donin et al., 
2003), as well as B-cell tumours (Kuraya et al., 1992), erythroleukaemic (Jurianz et al., 
2001) and renal cancer cell lines (Gorter et al., 1996). Other approaches include the 
downregulation of the CRPs expression (Bellone et al., 2012) or their removal from the 
cell surface (Geis et al., 2010). Various studies have also reported the use of mixtures of 
several antibodies to bypass the action of CRPs (Spiridon et al., 2002; Kennedy et al., 
2003; Macor et al., 2006). However, targeting inhibitory molecules to C regulators in vivo 
is technically challenging, because of possible unwelcome consequences for normal cells. 
An alternative approach would be to improve the C-mediated effector mechanisms of 
mAbs through genetic engineering or conjugation. Several strategies have been devised for 
turning non-C-fixing antibodies in those able to activate C, in order to be employed in 
immunotherapy. These include the selection of the IgG subclasses 1 (IgG1) and 3 (IgG3), 
that are most efficient in activating C, and the production of IgG1-containing recombinant 
variants of Fc, that exhibit increased capacity to induce CDC or ADCC (Ziller et al., 2005; 
Macor and Tedesco, 2007; Moore et al., 2010; Elvington et al., 2012). In addition, to 
overcome the inhibitory effect on the tumour microenvironment, some researchers have 
proposed the use of bispecific mAbs that target a tumour antigen and simultaneously block 
a major C regulatory protein (Gelderman et al., 2005; Macor et al., 2015). The potential of 
these antibodies is to enhance the clinical efficacy of therapeutic mAbs if delivered 
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selectively to their targets on cancer cells (Macor et al., 2015). To now, the molecular 
architecture of the antigens selected for immunotherapy, and the antibody concentration, 
still seem to be essential for the proper induction of CDC (Meyer et al., 2014). 
 
3.3    Complement activation can influence tumour growth 
Researchers have long thought that C activation in the cancer setting is 
extremely useful for proper elimination of tumour cells. However, recent data have also 
revealed a tumour-promoting role for the C system (Markiewski and Lambris, 2009b) 
(Figure 7). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Potential tumour-promoting roles of complement proteins. Complement proteins contribute to 
each major hallmark of cancer, including mitogenic signalling cascades and growth factor production, 
angiogenesis, protection from C-mediated lysis, cellular invasion and migration through the extracellular 
matrix, and suppression of antitumor immunity (Adapted from Rutkowski et al, Mol Cancer Res, 2010; 
8:1453–1465. Figure modified from Pio, Corrales and Lambris, Adv Exp Med Biol, 2014; 772:229–262).  
 
 
Markiewski and colleagues (Markiewski et al., 2008) first reported that C5a, generated in 
the tumour microenvironment as a result of  C activation, favours cervical cancer growth 
by recruiting and activating MDSCs, which worked to dampen a CD8+ T-cell-mediated 
anti-tumour response. This observation and similar findings in mouse models of lung 
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(Corrales et al., 2012) and ovarian cancers (Nunez-Cruz et al., 2012) challenge the concept 
that C activation at tumour site is always beneficial for cancer patients. 
However, the relevance of these in vitro and animal data remains to be established, and the 
clinical and therapeutic implications of these findings warrant further investigation as C5a 
has been found to exert opposite effects depending on the amount available in the tumour 
microenvironment (Gunn et al., 2012). Supporting this idea, Kim and colleagues has 
recently demonstrated a slower tumour growth in C5a expressing mammary sarcoma cells, 
compared to those lacking C5a in an in vivo mouse model (Kim et al., 2005). Irrespective 
of the beneficial or harmful effect of C on tumour growth, both effects have been found to 
be associated with C fragments, such as C3a and C5a, indicating complement activation 
(Sayegh et al., 2014). 
 
3.3.1    Role of the complement system in tumour angiogenesis and metastasis 
Recent evidences in literature demonstrate the ability of C to assist the escape 
of tumour cells by promoting angiogenesis and participating in tumour cell invasion and 
migration (Rutkowski et al., 2010). 
C-activated factors are related, either directly or indirectly, to neovascularization in cancer. 
Because of different types of tumour examined, there is still some controversy about the 
pro- or anti-angiogenic role of the C system in neovascularization (Pio et al., 2014). In a 
mouse model of epithelial ovarian cancer, a genetic C3 deficiency has been shown to 
impair tumour vascularization by altering the function of endothelial cells (Nunez-Cruz et 
al., 2012). However, in end point tumour specimens in a murine model of cervical cancer, 
C5a receptor (C5aR) blockade has been reported not to compromise tumour angiogenesis 
(Markiewski et al., 2008). Based on these results, Pio et al. suggested that C activation may 
be important in the promotion of angiogenesis only during the early steps of tumour 
formation (Pio et al., 2014). In vitro studies, using endothelial cells, support this 
conclusion. C5a has been recently demonstrated to stimulate chemotaxis and the formation 
of tube-like structures in both human umbilical endothelial cells (Corrales et al., 2012) and 
human microvascular endothelial cells (Nunez-Cruz et al., 2012). 
Rutkowski et al. reported that various C proteins might also contribute, either directly or 
indirectly, to release the metalloproteinases MMP-2/9 in the tumour microenvironment 
(Rutkowski et al., 2010), although their direct contribution in tumour invasion is still far 
from being clearly elucidated. 
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Chapter 4 
 
4.1    C1q: the first component of the complement system 
Extensive research conducted over the past 20 years has allowed us to identify 
in detailed the structural and functional role of human C1q in the activation of the classical 
pathway of the C system, as a well-recognized molecular sensor of damage-modified self 
or non-self antigens. In the last few years, increasingly data are emerging about its 
participation in a rapidly expanding list of pathological disorders, such as in placental 
development (Agostinis et al., 2010), preeclampsia (Singh et al., 2011), wound healing 
(Bossi et al., 2014) and cancer (Hong et al., 2009). In these diseases, either the soluble 
form, or the membrane-associated form, of C1q appear to be intimately involved. The 
chimeric structure of C1q, containing two functional domains, together with the fact that it 
is synthesized by a wide range of proinflammatory cell types, makes it likely that it is a 
potent orchestrator of molecular pathways involved not only in innate and adaptive 
immunity, but also in a wide range of inflammatory diseases, including cancer. 
(Ghebrehiwet et al., 2012). 
 
4.1.1    Cellular sources of human C1q 
C1q is the first component of the classical C activation pathway, belonging to 
the TNF superfamily of proteins (Kishore et al., 2004). This protein has been demonstrated 
to be highly conserved among more than a dozen of vertebrate species (Petry et al., 1996). 
Unlike most of the C proteins, which are produced in the liver, C1q is synthesized 
extrahepatically by a wide range of cell types, mainly macrophages (Petry et al., 2001), 
dendritic cells and fibroblasts, as well as epithelial, mesenchymal (Ghebrehiwet et al., 
2012), endothelial (Bulla et al., 2008; Bossi et al., 2014) and trophoblast (Agostinis et al., 
2010) cells. Recent papers showed the expression of C1q also in the central nervous 
system, by microglial cells (Lynch et al., 2004) and in the brain, by postnatal neurons 
(Stevens et al., 2007), as well as in the eye, by Retinal Ganglion Cells (RGCs) (Bialas and 
Stevens, 2013). The synthesized molecule in turn, is either transiently expressed as a cell 
membrane associated molecular ligand (mC1q), or secreted into the pericellular milieu, 
where it can modulate cell-specific biological responses in a manner that involves an 
autocrine and/or paracrine signalling through cell surface receptors and their signalling 
partners (Ghebrehiwet et al., 2012). 
 
 42 
 
4.1.2    The structure–function relationship of the human C1q 
The diversity of immunological functions mediated by C1q seem to be 
explained by having a unique structural feature. C1q consists of three similar, but distinct, 
polypeptide chains, A (28 kDa), B (25 kDa), C (24 kDa), which are the product of three 
distinct genes clustering in the same orientation, and in the order A–C–B, on a 24 kb 
stretch of DNA on chromosome 1p. Each of the three polypeptide chains consists of a C-
terminal globular “head” domain, also called gC1q domain, linked to a N-terminal 
“stalk”, known as collagen-like domain or cC1q domain. Of these, the gC1q domain, is 
considered to be key to the versatility of C1q function (Gaboriaud et al., 2003). These 
proteins are thus assembled to form disulfide-linked A–B and C–C dimers, while the A–B 
dimer is non-covalently (--) linked to the C-chain. Three A–B--C–C--B–A doublets are 
linked by non-covalent forces, to get a collagen-like hexameric glycoprotein of about 460 
kDa, resembling a “bouquet of tulips” (Ghebrehiwet et al., 2012) (Figure 8). Once formed, 
C1q associates with the Ca2+-dependent C1r2–C1s2 tetramer, of about 360 kDa, to form the 
soluble pentameric C1 complex. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Structural organization of C1q. The figure represents schematically the subunit structure and 
assembly of intact of C1q. Three similar chains, such as A, B and C, are assembled to form disulphide-linked 
A-B and C-C dimers. One strand of the molecule consists of an A-B dimer non-covalently (--) linked to a C 
chain forming (A-B--C). The C-chain of one strand is then disulfide linked to the C chain of a neighbouring 
strand to give an A-B--C-C--B-A doublet and three such doublets are linked by non-covalent forces giving 
C1q its signature “bouquet-like” structure (The figure adapted from Peerschkea and Ghebrehiwet, Mol 
Immunol, 2014; 61:100–109).  
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4.1.3    The main receptors of C1q  
C1q receptors comprise diverse cell surface and intracellular proteins, which 
recognize and bind to C1q, either via its gC1q or cC1q domain (Ghebrehiwet et al., 2012). 
These interactions mediate a plethora of immunologic functions (Nayak et al., 2012), 
including those associated with innate and adaptive immunity, and cancer (Peerschke and 
Ghebrehiwet, 2014). 
The receptor for the globular heads of C1q, gC1qR, also known as Hyaluronan-Binding 
Protein 1 (HABP1), p32 or p33, and the receptor for the collagen-like domain of C1q, 
cC1qR or calreticulin (CRT) are the two well-studied and ubiquitously distributed C1q 
receptors (Ghebrehiwet and Peerschke, 2004; Nayak et al., 2012). Although each of these 
molecules lacks a consensus sequence motif for a traditional transmembrane segment, the 
lack of direct conduit to intracellular signalling elements is bypassed by the formation of a 
docking/signalling complex with associated adapter proteins, such as CD91, CD44, DC-
SIGN and β1 integrin (Ghebrehiwet and Peerschke, 2004; Ghebrehiwet et al., 2012). 
Growing evidences show that both CRT and gC1qR are also implicated in carcinogenesis, 
albeit their roles seem to be rather divergent. Whereas cC1qR is reported to have tumour 
suppressive effect, gC1qR appears to be requisite for tumour cell progression and 
metastasis (Peerschke and Ghebrehiwet, 2014).  
 
4.1.3.1    gC1qR: the receptor for the globular heads of C1q  
The 33-kDa protein gC1qR is a multiligand binding protein, localized in every 
compartment of the cell, predominantly to the mitochondrial matrix and on the cell surface, 
and can be secreted by highly proliferating or activated cells. It has been shown to 
recognise and bind to the gC1q domain with high affinity interactions, under physiologic 
ionic strength (Peerschke and Ghebrehiwet, 2014). The binding site for gC1qR on C1q has 
been reported to be primarily on the C1qA chain, which is the same or overlapping site to a 
putative IgG site (Ghebrehiwet et al., 2012). Although the biologic significance of the wide 
distribution of gC1qR is yet to be elucidated, the relevance of gC1qR as an important 
modulator of ligands both inside and outside the cell is recognized increasingly (Dembitzer 
et al., 2012). The C1q/gC1qR interaction has been reported to lead to classical C pathway 
activation, with generation of inflammatory cytokines, as well as the binding of gC1qR to 
high-molecular-weight kininogen activates the kinin system, to produce bradykinin, 
ensuing vascular permeability (Peerschke and Ghebrehiwet, 2014). 
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To date, neither a mutation in the gC1qR gene, nor a genetic deficiency has been 
identified, which suggests that gC1qR is essential for survival (Peerschke and 
Ghebrehiwet, 2014). The human gene C1QBP, encoding the gC1qR protein, is located on 
the short arm of chromosome 17, in cytogenetic band 13.3 (17p13.3). Interestingly, 
bioinformatics analysis reveal that this region contains some of the major tumour 
suppressor genes, such as Tp53, BRCA1, as well as OVCA1 and OVCA2, which are 
frequently mutated in most cancer types, suggesting a potential role of gC1qR in 
carcinogenesis (Peerschke and Ghebrehiwet, 2014). 
Recent experiments (Dembitzer et al., 2012) compared the presence of gC1qR either in 
normal and malignant tissue of epithelial and mesenchymal origin. These histochemical 
analyses showed that the large majority, but not all, of the analysed human solid tumour 
tissues revealed marked differential expression of gC1qR compared to the non-malignant 
histologic counterparts (Peerschke and Ghebrehiwet, 2014). Recently, Fogal et al. showed 
that cell surface expressed gC1qR binds the tumour homing peptide LyP-1 (Fogal et al., 
2008). Moreover, knocking down gC1qR in cancer cells has been demonstrated to make 
them less tumorigenic (Fogal et al., 2010). The involvement of gC1qR in tumour 
promotion has been further substantiated by more recent studies, which reported that 
gC1qR in the membrane of human lung carcinoma A549 cells is a key regulator for 
lamellipodia formation and cancer metastasis via receptor tyrosine kinase activation (Kim 
et al., 2011). By contrast, two very recent papers demonstrated that increased gC1qR levels 
induce human cervical cancer cell apoptosis through mitochondrial dysfunction, by 
activating the p38 MAPK/JNK signalling pathway (Gao et al., 2013; Chen et al., 2014). 
Overall, the role of gC1qR in carcinogenesis is still contradictory, although Ghebrehiwet et 
al. have recently suggested its use as target for therapeutic intervention (Peerschke and 
Ghebrehiwet, 2014). Moreover, it remains to be established whether C1q acts in concert 
with gC1qR to sustain malignant transformation, tumour growth and invasion. 
 
4.1.3.2    Calreticulin: the receptor for the collagen-like domain of C1q (cC1qR)  
Calreticulin (CRT) is a 42-kDa molecule, belonging to the family of heat shock 
proteins, which is localized primarily in the lumen of the endoplasmic reticulum. CRT is 
expressed in all types of cells, with the exception of erythrocytes (Nayak et al., 2012). CRT 
is one of the crucial proteins responsible for calcium homeostasis, and together with its 
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homolog calnexin, regulates glycoprotein folding and quality control of nascent proteins as 
a molecular chaperon (Michalak et al., 2009). 
Surface expressed CRT, however, has been shown to play a major role in cellular 
adhesion, and in clearance of cell debris. The interactions between CRT and the 
collagenous region of C1q are crucial in apoptotic cell clearance via macrophages, with 
C1q opsonizing on the surface of apoptotic cells, and CRT linked to CD91 over the 
phagocyte cell surface (Nayak et al., 2012). However, CRT has optimal binding to C1q at 
sub-physiologic ionic strength, thus neutral pH has the ability to block most of the 
activities of C1q (Peerschke and Ghebrehiwet, 2014). CRT is also referred as the collectin 
receptor, due to its ability to bind to the collagen-like regions of various collectin, such as 
mannose-binding lectin (MBL), surfactant protein (SP)-A and SP-D (Nayak et al., 2012). 
Calreticulin has been found to be upregulated in most malignant cells (Zamanian et al., 
2013), where it functions as a pro-phagocytic signal, promoting macrophages to engulf 
hazardous cancerous cells. However, this “eat-me” signal is counterbalanced by the 
presence on tumour cells of the receptor for thrombospondin-1, CD47, which is able to 
block the functions of cC1qR (Chao et al., 2010). Blockade of the “don't-eat-me signal” 
CD47 on tumour cells may allow already expressed “eat-me” signals to induce 
macrophages to eliminate tumour cells. A recent study revealed a key molecular 
mechanisms adopted by macrophages to recognize and phagocyte tumour cells. This study 
demonstrated that the activation of Toll-like receptor pathways in macrophages induces the 
phosphorylation of Bruton's tyrosine kinase (Btk), which catalyses cell-surface exposure of 
CRT. Calreticulin on or secreted by macrophages plays a critical role in mediating adjacent 
tumour cell recognition and phagocytosis, playing an essential role in tumour surveillance 
and elimination (Feng et al., 2015). The group of Tosato and colleagues also found that the 
N-terminal domain of CRT is able to prevent tumour development, as well as to inhibit the 
growth of established ones, by interfering with endothelial cell growth and 
neovascularization. Moreover, this study demonstrated that the inhibition of endothelial 
cell proliferation was due to direct binding of the cC1qR fragment to the ECM protein, 
laminin, thereby interfering with endothelial cell attachment (Yao et al., 2002). Since 
adhesion and proliferation are key steps leading to neovascularization, and C1q has been 
shown to be a strong angiogenic factor (Bossi et al., 2014), it is possible to speculate that 
interfering with the C1q-cC1qR axis may provide a suitable therapeutic approach to fight 
against cancer. 
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On the other hand, evidence from numerous studies suggests that CRT overexpression is 
also a pro-tumourigenic event in various cancers. However, the exact roles of CRT is yet 
be clarified, due to its diverse interactions into various cellular processes and signalling 
pathways (Zamanian et al., 2013).  
 
4.2    The emerging functions of C1q independently on complement activation 
Besides the role of C1q as a C initiating molecule, it is also engaged in an array 
of processes that is completely independent of the C activation (Nayak et al., 2012). Most 
inflammatory cells, or those that undergo phenotypic differentiation or proliferation, are 
known to express and/or secrete C1q (Bulla et al., 2008; Ghebrehiwet et al., 2012). Recent 
evidences have revealed that locally secreted C1q modulates many cellular functions by an 
autocrine and/or paracrine signalling mechanism (Ghebrehiwet et al., 2012). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. The emerging and re-emerging functions of human C1q. The figure highlights the growing list 
of emerging and re-emerging non-traditional functions of C1q. Interaction of C1q with cell surface molecules 
plays a critical role in inflammation, as well as innate and adaptive immunity, by inducing a plethora of 
biological responses (Figure was adapted from Nayak et al., Immunol Lett, 2010; 131:139–150 and 
Ghebrehiwet et al., Front Immunol, 2012; 3, 1–9. The crystal structure was from Gaboriaud et al., Trends 
Immunol, 2004; 25:368–373).   
 
The locally synthesized C1q has recently been suggested to control microglial activation 
and recruitment (Färber et al., 2009). Fraser et al. showed that C1q has a neuroprotective 
role in the form of activating microglial cells, in order to ingest apoptotic neurons and by 
suppressing the production of pro-inflammatory cytokines (Fraser et al., 2010). 
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C1q mediates apoptotic cell clearance both in a C-dependent and C-independent manner. 
The non-C activating way of clearing apoptotic neurons and neuronal blebs is through C1q 
binding to CRT on macrophages and microglial cells which, in turn, leads to apoptotic cell 
phagocytosis through CD91-induced micropinocytosis (Ogden et al., 2001; Fraser et al., 
2009, 2010). 
C1q has been demonstrated to be associated in the maturation of dendritic cells (DCs) 
(Csomor et al., 2007; Nayak et al., 2010) and involved in modulating T-cell and B-cell 
activity (Nayak et al., 2012). 
The pro-proliferative function of C1q is not yet fully clarified. One of the first study 
reported that C1q induces an anti-proliferative signal in peripheral T cells (Chen et al., 
1994). In contrast, a recent study showed that C1q positively regulates CD8+ T-cell 
proliferation and also influences the cytokine profile of antigen-specific T-cells (van 
Montfoort et al., 2007). Moreover, C1q stimulates the production of IgG by B-lymphocytes 
and also plays a role in the negative selection of autoreactive B cells (Young et al., 1991). 
C1q is also involved in the migration of eosinophils, mast cells, neutrophils and fibroblasts, 
thus acting as a potent chemotactic molecule. This ability of C1q depends on the 
expression of gC1qR and CLR on the surface of these immune cells (Nayak et al., 2010). 
Several groups showed that C1q is able to bind to various ECM proteins with different 
affinity (Nayak et al., 2012). C1q binds strongly to decorin and biglycan, which are 
leucine-rich proteoglycans involved in matrix assembly and bone mineralisation, 
respectively (Groeneveld et al., 2005). In contrast, C1q binds to laminin (Bohnsack et al., 
1985) and fibronectin (Sorvillo et al., 1985) with a lower affinity. This binding has been 
implied in deposition and retention of immune complexes in the basement membrane 
(Sjöberg et al., 2009). Sjöberg et al. reported that the interaction between ECM proteins 
and C1q occurs without activating C, probably involving the CLR domain of C1q. 
Wherever the interaction involves the gC1q domain, C activation mostly results (Sjöberg et 
al., 2009). 
The nature of C1q involvement into non-C associated functions has been recently extended 
to pregnancy and development (Ghebrehiwet et al., 2012; Nayak et al., 2012). Our group 
showed that foetal trophoblast cells invading the decidua in the early stages of pregnancy 
not only actively synthesize and express C1q on their surface, but this C1q is actively 
involved in promoting trophoblast invasion of the decidua (Agostinis et al., 2010). This, in 
turn, is mediated by two cell surface receptors, gC1qR and α4β1 integrin, which promote 
trophoblast adhesion and migration through the activation of ERK1/2 MAPKs. In support 
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of these findings, Agostinis et al. also demonstrated that C1qa−/− mice manifested 
increased frequency of foetal resorption, reduced foetal weight, and smaller litter size when 
compared to their wild-type counterparts, suggesting that defective local production of C1q 
may be involved in pregnancy disorders, such as preeclampsia (Agostinis et al., 2010). 
The significance of C1q in pregnancy disorders has been further supported by an 
independent study, which showed that pregnant C1qa−/− mice express the key features of 
human preeclampsia that correlate with increased foetal death (Singh et al., 2011). 
More recently, Naito el al. reported that C1q activates canonical Wnt signalling and 
promotes aging-associated decline in tissue regeneration (Naito et al., 2012); moreover, our 
group showed that C1q is a strong angiogenic factor and promotes wound healing (Bossi et 
al., 2014). These studies suggest novel and unexpected roles of this C component, either in 
the modulation of mammalian aging, or in cancer neovascularization, respectively.  
 
4.3    C1q and tumourigenesis: first evidences and beyond 
The role of C1q in carcinogenesis is still largely elusive. To date, only few 
papers in literature indicate a possible direct involvement of this protein in neoplastic 
proliferation (Peerschke and Ghebrehiwet, 2014). As already previously described, the 
autocrine or paracrine signalling effects of C1q seem to occur through its cell surface 
receptors and signalling partners (Ghebrehiwet et al., 2012).  
The first indication that C1q may regulate cancer cell proliferation showed that the 
addition of soluble C1q to diverse types of cultured haematological tumour cell lines, 
expressing C1q receptors, such as the B-cells Raji, Daudi and Wil2-WT, the T-cells Molt4, 
and the monocytes U937, temporary inhibits tumour cell growth (Ghebrehiwet et al., 
1990). This study also reported that polyclonal F(ab’)2 and anti-C1q antibodies, as well as 
monoclonal antibodies against C1q receptors abrogate the antiproliferative effect of C1q. 
Based on these findings, Ghebrehiwet et al. suggested that C1q receptors alone, or in 
conjunction with other cellular factors, support cell growth upon ligand binding. The latter 
event has been thought to suppress post-receptor events, which are necessary for cell 
proliferation. More important, these early studies were performed in vitro using only 
haematological cancer cells, and lacked the necessary reagents to identify which of the two 
C1q receptors was responsible for the C1q-mediated tumor-suppressive or anti-
proliferative effect (Peerschke and Ghebrehiwet, 2014).  
A more recent study reported the involvement of C1q in the regulation of cancer cell 
survival and progression by inactivating the apoptotic cascade (Hong et al., 2009). C1q has 
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been shown to be expressed on basal and epithelial cells of prostate tissues, sustaining the 
activation of the tumour suppressor WW-domain containing oxydoreductase (WOX1), 
which is needed for blocking cancer cell proliferation. This data suggests that C1q may 
induce apoptosis of prostate cancer cells by activating WOX1 and destabilizing cell 
adhesion. The same authors also reported that the downregulation of C1q was found to 
enhance prostate hyperplasia and cancerous formation, due to failure of WOX1 activation. 
It is important to take into account that Hong et al. focused only on the prostate cancer, 
using the human DU-145 tumour cell line to perform all the experiments in vitro, without 
any evidence of tumour growth inhibition in vivo (Hong et al., 2009). In addition, this 
study lacked to unveil which of the two C1q domain was responsible for the C1q-mediated 
apoptosis. This study also revealed that C1q is significantly reduced in benign prostatic 
hyperplasia and prostate cancer tissues compared to the normal prostate (Hong et al., 
2009), although these findings are not corroborated by those obtained in other tumour 
types (Bulla, Tripodo, Rami et al., in submission). 
Ghebrehiwet et al. has recently suggested that these evidences highlight the “cytokine-like” 
activity of C1q (Ghebrehiwet et al., 2012), while the functions exert by locally expressed 
C1q in the tumour microenvironment are still unknown. 
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RATIONALE AND AIMS OF THE STUDY 
 
The complement (C) system is part of the local microenvironment acting as a 
bridge between innate and adaptive immunity and taking part in immune surveillance and 
homeostasis. The activation of the C system has been demonstrated to exert an active and 
beneficial role in the fight against malignant cells, based on the ability to promote 
inflammation and to cause direct cell killing. The advantage of this defence system is to be 
made up of several components readily available at the tissue site, where they are secreted 
by various stromal and immune cells surrounding the tumour mass, and also by tumour 
cells or recruited from the circulation as result of an inflammatory process. 
Circumstantial evidences obtained from the analysis of different tumour tissue types 
showing deposition of C activation products on cancer cells have suggested a role for C in 
the immune surveillance of cancer. Although C has proven to be an efficient weapon to 
control tumour growth, provided that the membrane-bound C regulatory proteins (CRPs) 
on cancer cells are neutralized, a recently published Nature Immunology paper and others 
have challenged the concept that increased C activation at tumour site is merely beneficial 
for cancer patients. 
Here we present novel data showing that C can adopt an alternative strategy that does not 
require activation of the system to promote cancer progression and invasion. 
Guided by our recent findings that the first component, C1q, promotes trophoblast 
migration through the decidua during pregnancy and exerts a pro-angiogenic effect in 
wound healing, we aimed to investigate the role of the locally produced C1q in the tumour 
microenvironment. 
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MATERIALS AND METHODS 
 
Antibodies and reagents 
The following antibodies were used: rabbit antiserum to human C1q (Dako); 
goat antiserum to human C3, C4, C1s (Quidel); rat monoclonal anti-mouse C1q (clone 
7H8; HyCult) and rabbit polyclonal anti-mouse C1q (kindly provided by Prof M. Daha, 
Leiden, The Netherlands); FITC-conjugated F(ab′)2 fragment goat anti-mouse C3 (Cappel) 
and rat monoclonal anti-mouse C4 (clone 16D2; HyCult); rabbit polyclonal pan-specific 
Von Willebrand Factor (code number A0082; Dako); rat monoclonal anti-mouse CD68 
(clone FA-11; AbD Serotec); rabbit polyclonal anti-mouse Ki-67 (code number 15580; 
Abcam); FITC-labeled swine anti-rabbit IgG (code number F0205), TRITC-labeled swine 
anti-rabbit IgG (code number R0156) and FITC-labeled rabbit anti-rat IgG (code number 
F0234) (Dako); polyclonal Cy3-coniugated F(ab')2 fragment goat anti-rabbit IgG (H+L) 
and polyclonal Alexa Fluor 488 goat anti-rat IgG (H+L) (Jackson ImmunoResearch); 
alkaline phosphatase-conjugated goat anti-rabbit IgG and rabbit anti-goat IgG (Sigma–
Aldrich). The following reagents were used: fibronectin (FN) (Roche, Milan, Italy), 
Polylysine (PolyLys) and bovine serum albumin (BSA) (Sigma-Aldrich). Purified C1q, 
was purchased from Sigma–Aldrich and its purity was checked by SDS/PAGE analysis.  
 
Human tissues  
Tumour tissue samples were obtained from the archives of the Department of 
Human Pathology, University of Palermo, Italy. Thirty invasive malignant neoplasm 
specimens were selected including six cases of each of the following tumour type, such as 
colon adenocarcinoma, melanoma, lung adenocarcinoma, breast adenocarcinoma, and 
pancreatic adenocarcinoma. The study was approved by the Institutional review board of 
the University of Palermo. 
 
Mice  
C57BL/6 WT mice were purchased from Harlan Laboratories. Mice deficient 
in complement components C1q, C3 or C5 (respectively C1qa-/-, C3-/- and C5-/-) were 
generated as described previously (Botto et al., 1998; Wessels et al., 1995; Wetsel et al., 
1990). All strains were backcrossed onto the C57BL/6 (B6) genetic background for more 
than 10 generations. The mice were sex- and age-matched. All animals were handled in 
accordance with the institutional guidelines and in compliance with the European 
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(86/609/EEC) and the Italian (D.L.116/92) laws. Procedures were approved by the 
Institutional Animal Care Committee of the University of Trieste and by the UK Home 
Office.  
 
In vivo tumour models 
B16/F10 murine melanoma cell line was purchased from the American Tissue Culture 
Collection (Manassas, VA) and maintained in Minimum Essential Medium (Euroclone) 
supplemented with 10% (v/v) Fetal Bovine Serum, 1% (v/v) Penicillin–Streptomycin 
solution, 2 mM L-Glutamine, 100 μM Non-Essential Amino Acids, 1 mM Sodium 
Pyruvate and 10 mM HEPES (all from Life Technologies) in a humidified 5% CO2 
atmosphere at 37°C. C57BL/6 WT, C57BL/6.C1qa-/-, C57BL/6.C3-/- or C57BL/6.C5-/- 
were injected intramuscularly into the left flank of the mice (2×106) with viable B16/F10 
cells and tumour development was monitored over time. Tumour volume was measured 
with calliper by determining two orthogonal axis, and calculated using the following 
formula: (π/6)•α2•β, with α the shorter and β the longer axis (Gava et al., 2006). At day 14 
the animals were sacrificed and tumours, spleens and lungs were collected for analyses. 
 
Bone marrow transplantation (BMT) and assessment of C1q levels 
Mice were irradiated at 8 Gy using a 137Cs γ-ray source and reconstituted with 
107 bone marrow cells from sex-matched WT or C1qa-/- donors. Mice were kept under 
sterile conditions for the first two months after BMT. The successful reconstitution of the 
haematopoietic lineages after BMT was monitored by flow cytometry and by measuring 
C1q levels in serum. Two months after the BMT mice were injected intramuscularly with 
2×106 viable B16/F10 cells and tumour growth monitored up to day 14. Serum C1q levels 
were measured by ELISA as previously described (Petry et al., 2001; Cortes-Hernandez et 
al., 2004). Briefly, microtiter plates were coated with 1 μg/ml of anti-mouse C1q Ab (clone 
Rm C7H8; Connex) and blocked with 5% milk in PBS. Serum samples were diluted 
appropriately in PBS-2% BSA-0.05%Tween 20-0.02% NaN3. Bound C1q was detected 
with a biotinylated goat anti-mouse C1q antibody (kindly provided by Prof F. Petry, 
Mainz, Germany) followed by a streptavidin-alkaline phosphatase conjugate (BD 
Bioscience, San Diego, Ca), and revealed with p-Nitrophenyl Phosphate (pNPP) alkaline 
phosphates substrate (Sigma). Optical density (OD) was measured at 405 nm. The results 
were expressed in μg/ml, referring to a standard curve derived from a known concentration 
of purified human C1q. C1q-deficient mouse serum was included as negative control. 
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Immunohistochemical staining  
Four-micrometer-thick paraffin tissue sections were stained for 
immunohistochemical analysis as previously reported (Bulla et al., 2008; Bossi et al., 
2014). After microwave antigen retrieval, the sections were incubated overnight with C1q 
(Dako, Denmark), C1s (Quidel, USA), C3 (The Binding Site, UK), C4 (The Binding Site, 
UK) and CD31 (Novocastra, UK) primary antibodies and staining was revealed by 
streptavidin–biotin–peroxidase complex method. 3-Amino-9-ethylcarbazole (AEC; red 
signal, DAKO, Denmark) was used as a chromogenic substrate, and sections were 
counterstained with Hematoxylin. Negative control stainings were performed by using 
mouse, rabbit, or goat immune sera instead of the primary antibodies. For double-marker 
immunohistochemistry, sections underwent two sequential rounds of single-marker 
immunostaining. Briefly, the samples were incubated with mouse anti-human CD34 
(Novocastra, UK), and after Fc blocking, with rabbit anti-human C1q (Dako, Denmark). 
The binding was revealed using specific secondary antibodies phosphatase alkaline or 
peroxidase conjugated (Sigma, USA) and BCIP/NBT and AEC as substrates respectively. 
 
Immunofluorescence analysis  
Seven-micrometer-thick tissue sections of snap-frozen tumour masses from 
WT and C1qa-/- mice at the indicated time-points, embedded in OCT medium (Diagnostic 
Division; Miles Inc), were stained for immunofluorescence analysis with the appropriate 
antibodies and incubated with DAPI (Sigma-Aldrich) to counterstain cell nuclei. The slides 
were mounted with the Mowiol based antifading medium (Sigma-Aldrich). Images were 
acquired with fluorescence microscope Leica DM2000 (Leica Microsystems, Wetzlar, 
Germany) equipped with Leica DFC420 camera. 
 
Confocal analysis  
B16/F10 cells (3×105) were plated at 37°C on eight-chamber culture slides (BD 
Biosciences) coated with C1q (20 μg/ml), FN (20 μg/ml), FN+C1q (20 μg/ml each) or 
PolyLys (70 μg/ml) and left to adhere for 30 min. The cells were fixed and permeabilized 
with the FIX & PERM Cell Permeabilization Kit (Società Italiana Chimici, Roma, Italy), 
stained with N-(7-nitrobenz-2-oxa-1,3-diazol-4-y)-conjugated phallacidin (NBD-
phallacidin) (Molecular Probes, Invitrogen) and mAb anti-paxillin followed by Cy3-
conjugated F(ab’)2 goat anti-mouse IgG as previously described (Spessotto et al., 2006; 
Agostinis et al., 2010). Images were acquired with the Leica TCS SP2 confocal system 
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(Leica Microsystems) using the Leica Confocal Software and a 633 fluorescence objective 
on a Leica DM IRE2 microscope (Leica Microsystems) or with a Nikon C1Si confocal 
system, using the Nikon EZ-C1 Confocal Software and a 633 fluorescence objective on a 
Nikon TE2000-U inverted microscope (Nikon, Melville, NY). 
 
Evaluation of angiogenesis and metastases  
The microvascular density was evaluated on CD31-immunostained sections 
from mouse tumour samples by counting the number of vessels out of 10 microscopic 
fields at ×200 magnification and averaging the counts. The number of lung parenchymal 
metastases was evaluated on H&E-stained sections and the overall metastatic burden was 
assessed as the sum of the areas of the metastatic foci in the evaluated sections. All the 
measurements were performed using a Leica DMD108 digital microscope. 
 
Flow cytometry 
Cells were stained using standard protocols in the presence of a saturating 
concentration of anti-CD16/CD32 (2.4G2) mAb. The following antibodies were used: anti-
CD4 (clone RM4-5), anti-CD8a (clone53-6.7), anti-CD11b (clone M1/70), anti-CD14 
(clone Sa2-8), anti-CD45 (clone 30-F11), anti-CD49b (clone Dx5) and Gr-1 (clone RB6-
8C5). Antibodies were all purchased from eBioscience (Life Technologies, Paisley, UK). 
Data were acquired using a FACSVerse (Becton-Dickinson, Mountain View, CA) and 
analysed using FlowJo software, version 7.6 (TreeStar, Ashland, OR). 
 
Adhesion assay 
The adhesion assay was performed as previously reported (Agostinis et al., 
2010). Briefly, 1×105 B16/F10 cells/100 µl [RPMI 1640 (Life technologies) containing 
0.1% (v/v) BSA], labelled with the fluorescent dye FAST DiI (Molecular Probes, 
Invitrogen), were added to a 96-well plate (Iwaki, Bibby Scientific Italia, Milan, Italy) for 
35 min at 37°C in an air/CO2 incubator. The wells were coated with BSA, C1q and FN 
used at the concentration of 20 µg/ml in pH>9 sodium bicarbonate-buffered medium (100 
mM). Double-coated wells were prepared by adding first FN (20 µg/ml) and then 
incubated with C1q (25 µg/ml) in PBS-BSA 0.1% (v/v) and 0.7 mM Ca2+ and Mg2+ for 90 
min at 37°C, to allow the interaction of C1q with bound FN. The number of adherent cells 
were counted with Infinite200 (absorbance 544 nm, emission 590 nm) (TECAN Italia, 
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Milan, Italy) and referred to a calibration curve established with an increasing number of 
labelled cells. 
 
Assessment of Ki-67 expression 
The proliferation assay was performed by modifying the protocol previously 
reported (Bossi et al., 2014). Briefly, serum-starved B16/F10 (8×104 cells) for 24 hours 
were seeded for 6 hours on eight-chamber culture slides (BD Biosciences Discovery 
Labware, Milan, Italy) coated with PolyLys (70 μg/ml), C1q (20 μg/ml), FN (20 μg/ml) or 
double-coated wells as described above in serum-free culture medium with 0.5% (v/v) 
BSA and 0.7 mM Ca2+ and Mg2+. The cells were fixed and permeabilized with the FIX & 
PERM Cell Permeabilization Kit (Società Italiana Chimici), and stained with the anti-
mouse Ki-67, followed by the FITC-labelled secondary antibody. The percentage of Ki-67-
positive tumour cells was then determined by relating the total number of DAPI-positive 
nuclear staining to the total number of Ki-67-positive tumour cells in ten fields with an 
high-density number of cells (×200). The mean value was calculated for each section. 
 
Migration assay 
The migration assay was performed as previously reported (Agostinis et al., 
2010). The migration assay was performed in transwell chambers using FAST DiI-labeled 
(Molecular Probes, Invitrogen) B16/F10 cells (2×105 cells), resuspended in RPMI 1640 
with 0.1% (v/v) BSA and added to the upper chamber. The cells were allowed to migrate 
through HTS FluoroBlok systems with polycarbonate membranes of 8 μm pore size 
(Becton Dickinson, Falcon, Milan, Italy) coated on the upper side with BSA, C1q and FN 
used at the concentration of 20 µg/ml in pH>9 sodium bicarbonate-buffered medium (100 
mM). Double-coated wells were prepared as described above. The cells were left to 
migrate for 18 hours. The number of cells transmigrated to the lower side of the insert was 
evaluated as outlined above for the adherent cells. 
 
Phosphorylation of ERK, Akt and GSK-3β in mouse melanoma cell line 
Pathway analysis was performed according to the manufacturer’s instructions 
of the PathScan® Intracellular Signaling Array Kit (Fluorescent Readout) (code number 
7744; Cell Signaling Technology, EuroClone, Milan, Italy). Briefly, 24 hours serum-
starved B16/F10 cells (1.8×106 cells) were left to adhere to PolyLys-, C1q-, FN- or double-
coated wells as described above for the indicated periods of time at 37°C. At the end of the 
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incubation period, the cells were washed with ice-cold 1X PBS and lysed in 1X ice-cold 
Cell Lysis buffer, containing a cocktail of protease inhibitors (1X) (Roche Diagnostics). 
The Array Blocking Buffer was added to each well and incubated for 15 min at RT. 
Subsequently, an equal amount of total lysate (0.8 mg/ml) was added to each well and 
incubated for 2 hours at RT. After washing, the biotinylated detection antibody cocktail 
was added to each well and incubated for 1 hour at RT. Streptavidin-conjugated DyLight 
680 was added to each well and incubated for 30 min at RT. Fluorescence readout was 
acquired using the LI-COR Biosciences Infrared Odyssey imaging system (Millennium 
science) and pixel intensity was quantified using Array Vision software.  
 
Statistical analysis 
Data from in vivo mouse models were analysed using Two-way ANOVA, 
Tukey-Kramer test, survival data by Kaplan-Meier test and in vitro experiments with 
unpaired two-tailed Student t test. Results were expressed as mean ± SEM. Ex vivo 
analysis were assessed by Mann–Whitney U tests. Results were expressed as median and 
interquartile range. P values of less than 0.05 were considered significant. All statistical 
analyses were performed using Prism 6 software (GraphPad Software Inc, La Jolla, CA). 
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RESULTS 
 
C1q is present in human tumour specimens 
We have recently reported that C1q favours trophoblast invasion of maternal 
decidua (Agostinis et al., 2010) and promotes angiogenesis in wound healing (Bossi et al., 
2014). As these features are shared to some degree by growing tumours, the possibility that 
C1q may contribute to this process was raised. To support this notion we initially searched 
for the presence of C1q, C1s, C4, and C3, in a panel of 30 invasive malignant neoplasm 
specimens including 6 cases of each of the following tumour type, such as colon 
adenocarcinoma, melanoma, lung adenocarcinoma, breast adenocarcinoma, and pancreatic 
adenocarcinoma. As shown in Figure 1, a strong signal for C1q was detected in all tumour 
specimens examined, while other complement components were either absent (C4) or 
mildly expressed (C1s and C3) suggesting that C1q deposition did not result in the 
activation of the classical pathway. Within the tumour microenvironment, C1q was mainly 
expressed by vascular endothelia (Figure 1B, black arrows), mesenchymal cells and 
histiocytes (Figure 1B, black arrowheads). C1q expression within newly formed tumour-
associated vascular endothelia was further confirmed by double-staining with CD34, an 
endothelial marker, which revealed co-localization (Figure 1C). Notably, C1q expression 
in the mesenchymal elements appeared to be associated with cancer invasion since C1q 
was clearly detected in stromal elements at the tumour invasion edge, whereas it was 
absent in the distant stroma (Figure 1D, left panel, black arrows). Consistent with this, C1q 
was not detected in non-transformed and non-infiltrated peri-tumoural tissues (Figure 2). 
Moreover, the association between C1q expression and tumour stroma was not confined to 
primary lesions as it was also detected in the stroma of metastatic tumour foci (Figure 1D, 
right panel, black arrows). 
 
Prolonged survival and decreased tumour growth in C1q-deficient mice  
The presence in tumour tissues of C1q in the absence of other components of the classical 
complement pathway led us to evaluate the contribution of this molecule to tumour growth 
in a syngeneic model of melanoma developed in C57BL/6 (WT) mice. After pilot 
experiments to define the optimal experimental conditions for inducing tumour growth and 
lung metastasis in a high proportion of mice, we selected the intramuscular injection of 
2×106 B16/F10 melanoma cells. The tumour mass grew progressively in WT 
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Figure 1. (A) Immunohistochemical analysis of human tumours for the presence and distribution of 
complement components. Representative microphotographs of immunohistochemical analyses for the 
complement components C1q, C1s, C3, and C4 performed on different malignant cancer histotypes showing 
the consistent expression of C1q in the tumour-associated stroma in spite of a scant or absent expression of 
other C components involved in the classical pathway. Streptavidin-biotin-peroxidase complex system with 
AEC (red) chromogen. Original magnification ×200. 
(B) Analysis of tissue distribution of C1q. C1q expression in the tumour-associated stroma of the different 
cancer histotypes highlights monocytoid cells suggestive of tumour-infiltrating myeloid elements 
(arrowheads) and mesenchymal elements including vascular endothelial cells and spindle-shaped fibroblasts 
A 
B 
C D 
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(arrows). Streptavidin-biotin-peroxidase complex system with AEC (red) chromogen. Original magnification 
×630. 
(C) Colocalization of CD34 and C1q on the vessel endothelium of colon cancer. Actual expression of 
C1q on tumour stroma vascular endothelia is demonstrated by double-marker immunohistochemical analysis 
showing co-localization of C1q (blue signal) and CD34 (red signal) in vessels. Streptavidin-biotin-peroxidase 
complex system with AEC (red) and alkaline-phosphatase-anti-alkaline-phosphatase method with NBT/BCIP 
(blue) chromogen. Original magnification ×400. 
(D) Deposition of C1q at the infiltration edge and in liver metastasis of colon cancer. Left panel: stromal 
expression of C1q characterizes the stromal tissue neighbouring neoplastic glandular foci at the edge of 
tumour infiltration in colon adenocarcinoma infiltrating the muscularis propria (arrows), while the distant 
stroma has no significant C1q expression. Right panel: C1q expression also characterizes the tumor-
associated stroma (particularly the fibrovascular meshwork) at sites of metastatic colonization as shown in a 
parenchymal liver metastasis by colon adenocarcinoma. Streptavidin-biotin-peroxidase complex system with 
AEC (red) chromogen. Original magnification ×400.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Representative microphotographs showing differential C1q expression in the stroma of 
cancer-involved (left edge of the upper panel; red contoured panel) and non-involved mucosa (right edge 
of the upper panel; green contoured panel). C1q-expressing tumour-infiltrating myeloid elements 
(arrowheads) and mesenchymal elements including vascular endothelial cells and spindle-shaped fibroblasts 
(arrows) are differently enriched in the two conditions. Streptavidin-biotin-peroxidase complex system with 
AEC (red) chromogen. Original magnifications: upper panel ×200; lower panels ×630. 
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animals reaching a mean of 6 cm3 20 days after the cell injection (Figure 3A). Thereafter, 
the mice started to die and were all deceased within 32 days (Figure 3B). Conversely, 
C1qa-/- mice exhibited a significantly slower tumour growth throughout the period of 
observation associated with a prolonged survival, while the tumour growth and the survival 
rates of both C3- and C5-deficient animals did not differ from those of WT animals (Figure 
3A-B). 
Immunofluorescence analysis of the tumour masses showed marked deposition of C1q on 
vascular endothelium and stroma in the absence of C4 and a scattered distribution of C3 
that was undetectable on endothelial cells and was mainly associated with tumour 
infiltrating cells (Figure 3C). To identify the cell source of C1q and C3, double staining of 
tumour sections was performed with antibodies to CD68 and each of the two complement 
components. As shown in Figure 3D, C3 was expressed almost exclusively in CD68+ 
macrophages while C1q staining was seen both in CD68+ macrophages and in CD68- 
mesenchymal stromal cells. Kinetic analysis of  the growing tumour revealed the presence 
of C1q as early as 2 days after tumour cell injection preceding the expression of C3 that 
started to be detected two days later and was clearly seen on day 6 (Figure 3E). 
  
Distinct features of melanoma in WT and C1qa-/- mice 
To validate the results of the different tumour progression observed in C1qa-/- 
and WT mice, the in vivo experiment was independently repeated in another institution’s 
animal facility using B16/F10 cells. The data shown in Figure 3F-G essentially confirm the 
slower growth rate and the markedly reduced size of tumour in C1qa-/- mice as compared 
with WT animals. The possibility that C1q expressed in the tumour microenvironment may 
promote tumour growth by modulating the local immune response was explored by flow 
cytometry analysis of tumour-infiltrating immune cells. No difference was found in the 
percentage of cells of both the innate (NK, monocytes and macrophages) and adaptive 
(CD4+ and CD8+ T cells) immune system (Figure 3H). In addition, we failed to detect a 
higher percentage of myeloid derived suppressor cells in WT mice that may explain the 
enhanced tumour growth in these animals as compared with C1qa-/- mice (Figure 3H). 
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Figure 3A-D. Effect of C1q on tumour growth and survival of B16/F10 bearing mice. WT (n=14),  
C1qa-/- (n=7), C3-/- (n=11) and C5-/- (n=10) mice received an intramuscular injection of 2×106 B16/F10 
melanoma cells and the tumour size (A) and survival (B) was analysed at various days after cell injection. 
Data of tumour size are presented as mean ± SEM. ** p<0.01 (two-way ANOVA, Tukey-Kramer test). 
Survival data have been analysed by Kaplan-Meier test (C1qa-/- vs WT p<0.01; C1qa-/- vs C3-/- p<0.01;  
C1qa-/- vs C5-/- p<0.01; C3-/- or C5-/- vs WT not significant). (C) Immunofluorescence analysis of tumour 
tissue for the distribution of the C1q, C4, C3 and endothelial vWF at day 14. (D) Immunofluorescence 
staining of tumour tissue for C1q, C3 and macrophage CD68 at day 14. Nuclei were stained with DAPI. 
Original magnification ×200. 
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Figure 3E. Expression of C1q and C3 in tumour tissue collected from WT mice at various days after 
B16/F10 injection. Immunofluorescence analysis of tumour tissue for the presence of the C1q and C3 at day 
2, 4 and 6 after the intramuscular injection of 2×106 B16/F10 melanoma cells. Nuclei were stained with 
DAPI. Original magnification ×200. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3F-G. Evaluation of tumour size in tumour bearing WT and C1q-deficient mice. (F) Tumour 
mass of C1q-deficient mice (n=7; triangle) and WT mice (n=7; circle) measured on various days after 
B16/F10 melanoma cell injection. Data are shown as mean ± SEM. ** p<0.01, Student t-test. (G) Imagine of 
the tumours and spleens of one representative experiment on sacrificing (day 12). Scale bar, 1 cm.  
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Figure 3H. Percentage of different cell populations within the tumour mass on day 12 after the 
B16/F10 injection. Upper panel - Tumour tissues were mechanically disaggregated and the infiltrating 
leukocytes were separated by gradient centrifugation on Histopaque. Representative data from 2 independent 
experiments are shown. Statistical analysis by two-tailed t-test, p values are indicated. Each symbol 
represents one mouse and the lines designate means ± SEM. Left panel - representative flow cytometric plot 
showing the gate strategy used to identify the mononuclear MDSCs (MO-MDSCs) and polymorphonuclear 
MDSCs (PMN-MDSCs) among CD45+ tumour infiltrating cells. PMN-MDSCs were characterized by higher 
expression of CD11b and Gr-1 compared to MO-MDSCs. Right panel - ratio of PMN-MDSCs to MO-
MDSCs in total tumour MDSC populations of WT and C1q-deficient mice. P value is indicated, t-test. Each 
symbol represents one mouse and the line designates mean ± SEM. 
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Effect of C1q on tumour angiogenesis and metastases 
As cancer development largely depends on angiogenesis (Carmeliet, 2005), we 
examined the tumour tissue for the degree of new vessel formation and discovered that the 
vascular density in tumour bearing WT mice was significantly higher than that in C1qa-/- 
animals, particularly in the peri-tumoural area (Figure 4A-D). We also searched for 
metastatic melanoma cells in the lungs, the target organ preferentially colonized by the 
cancer cells that escape from the primary tumour site (Braeuer et al., 2014), and found 
metastases in 6 out of 11 WT mice and only in 1 out of 12 C1qa-/- mice (Figure 4E-F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4A-F. Evaluation of angiogenesis and lung metastases in tumour-bearing mice. Quantification of 
intra-tumoural (A) and peri-tumoural (C) microvascular density (MVD) on five different ×200 microscopic 
fields of tumour sections from WT and C1q-deficient mice immunostained for CD31. Representative pictures 
of CD31 immunostained sections of tumour tissue from WT and C1q-deficient mice showing intra-tumoural 
(B) and peri-tumoural (D). Measurement of metastatic areas in the lungs of tumour bearing WT (n= 11) and 
C1q-deficient mice (n=12) (E) and representative images showing metastases in both group of mice (F). Data 
are expressed in μm2 as median and interquartile range. * p<0.05, ** p<0.01, *** p<0.0002 (Mann–Whitney 
U test).  
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Tumour growth in bone marrow transplanted mice  
To investigate whether the manipulation of C1q levels by BMT could influence 
the development of the tumour, we produced reciprocal radiation BM chimeras between 
C1qa-/- and WT mice. In agreement with our previous findings (Petry et al., 2001; Cortes-
Hernandez et al., 2004), two months after the BMT, C1q levels in the C1q-deficient host 
were almost comparable to those in control WT chimeras (Figure 5B). In contrast, the C1q 
levels in WT mice reconstituted with C1qa-/- BM cells were hardly detectable. The 
development of the tumour in the bone marrow chimeras was then evaluated by measuring 
the tumour size at different time points (Figure 5A). A progressive increase in tumour was 
observed in all experimental groups during the period of observation. However, at each 
time point this increase was markedly less pronounced in the C1qa-/- irradiated recipient 
mice regardless of the circulating C1q levels. Syngeneic reconstituted C1qa-/- mice (; 
718.9±364.1 mg) and the chimeric mice becoming C1q-sufficient (; 240.8±104.8 mg) 
after BMT developed smaller tumours. Conversely WT mice reconstituted with C1qa-/- 
BM cells (; 2587±1391 mg) and syngeneic (; 6750±1715 mg) reconstituted WT mice 
showed accelerated tumour growth (Figure 5A). Taken together these data indicate that the 
non-bone marrow derived C1q was a critical factor for the tumour growth. The cell source 
of C1q was analysed by immunofluorescence using antibodies to C1q (red) and to CD68 
(green) to identify bone marrow derived macrophages (Figure 5C). As expected, C1q was 
undetectable in C1qa-/- mice reconstituted with C1qa-/- BM while it was widely distributed 
on endothelial cells and in CD68+ cells in WT mice receiving WT BM. Vascular 
endothelium and CD68- non-BM derived stromal cells expressed C1q in WT mice 
reconstituted with C1qa-/- BM. Conversely, endothelial cells did not stain for C1q in   
C1qa-/- recipient of WT BM that colonize the tumour mass with macrophages expressing 
C1q.  
 
Biologic effects of C1q on murine melanoma cells 
Having established that C1q is present in the tumour mass, we sought to 
investigate the mechanism by which C1q contributed to tumour growth analysing its ability 
to promote adhesion, proliferation and migration of cancer cells. To evaluate cell binding 
to C1q, melanoma cells were labelled with the fluorescent probe FAST Dil and allowed to 
adhere to solid phase-bound C1q or a mixture of FN and C1q, in 96-well plates for 30 min 
at 37°C, using BSA and FN as negative and positive controls, respectively. C1q was able 
to promote the adhesion of 29% of cells as opposed to nearly 13% of cells adhering to 
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Figure 5A-C. Tumour growth in BM transplanted mice. (A) Tumour mass measured on various days after 
tumour cell injection (left graph) and on end-point (day 16) when mice were killed and tumours were 
removed (right graph). Irradiated recipient mice are represented by a circle (WT) or a triangle (C1qa-/-). Mice 
reconstituted with C1q-sufficient BM cells are represented with a closed symbol while those reconstituted 
with C1q-deficient BM cells with an open symbol. Data are shown as means ± SEM. Each symbol represents 
an individual mouse; p values are indicated (two-way ANOVA). (B) C1q antigenic levels in reconstituted 
mice. Levels were measured by ELISA as described in the Materials and Methods section after two months 
after BMT. Results are expressed in g/ml, referring to a standard curve derived from a known concentration 
of purified C1q. (C) Localization of C1q (red) and macrophage CD68 (green) in tumour section of BMT 
mice. Nuclei were stained with DAPI. Original magnification ×200. 
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BSA and enhanced the pro-adhesive activity of FN to approximately 80% following its 
interaction with this ECM protein (Figure 6A). A high percentage of cells bound to FN 
appeared spread out and displayed actin-containing stress fibres, in contrast with the round 
morphology exhibited by the great majority of those attached to C1q and by a proportion 
of cells adhering to C1q bound to FN (Figure 6D). 
The ability of C1q to induce cell migration was examined by adding the tumour cells to the 
upper chamber of a transwell and allowing them to migrate through an insert coated with 
C1q or FN or both. C1q was slightly more effective than FN causing migration of 87 % of 
cells that increased to 96% using the mixture of C1q and FN (Figure 6B), and the 
difference was statistically compared to FN.  
Given the in vivo finding that C1q present in the tumour microenvironment is associated 
with cancer progression, we asked the question whether C1q may contribute to tumour 
growth by stimulating the proliferation of cancer cell. To this purpose, the melanoma cells 
were incubated with solid–phase bound C1q and either FN or the mixture of FN and C1q 
for 6 hours and the number of proliferating cells was evaluated using anti-Ki-67 antibody. 
As shown in Figure 6C, C1q induced significantly higher cell proliferation than FN (40% 
vs 27%) and the percentage of proliferating cells slightly increased after stimulation with 
the mixture of C1q and FN.  
To further elucidate the mechanism of cell activation, we analysed the signalling pathways 
potentially involved in tumour cell adhesion, migration and proliferation examining more 
specifically the activation of ERK1 and the regulation of Akt and GSK-3β signalling 
molecules.  
To this purpose, 24 hours serum-starved B16/F10 cells were allowed to adhere to wells 
coated with C1q, FN or the mixture of C1q and FN for various lengths of time and the 
phosphorylation status of ERK1 (Thr202/Tyr204), GSK-3β (Ser9) and Akt (Thr308 and 
Ser473) was evaluated by immunofluorescence using specific antibodies. As shown in 
Figure 6E-H, binding of B16/F10 cells to C1q resulted in the activation of all the signalling 
molecules, which was already seen at 20 min and substantially decreased or became 
undetectable at 40 min post-stimulation. Interestingly, the phosphorylation level of all the 
signalling molecules in cells seeded onto double matrix (FN+C1q) was greater than the 
combined values observed in FN- and C1q-stimulated cells. This was particularly evident 
when analysing the phosphorylation level of GSK-3β and Akt (Ser473) in double matrix-
activated  cells that by far exceeded  those induced by FN and C1q tested individually. 
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Figure 6. Effect of C1q on B16/F10 melanoma cell adhesion, migration and proliferation, as well as 
C1q-mediated cell signalling. (A-C) The experiments of cell adhesion, migration and proliferation were 
performed as detailed in Materials and Methods. Data from at least five independent experiments are 
presented as mean ± SEM. * p<0.05, ** p<0.01 (Student t test). (D) Confocal analysis of B16/F10 seeded 
on slides coated with different matrix. Tumour cells fixed after incubation on C1q, FN and FN+C1q for 30 
min and stained with NBD-phallacidin (green) and mouse monoclonal anti-paxillin Ab followed by Cy3-
conjugated goat anti-mouse IgG (red) were analysed by confocal microscopy. Original magnification: ×630. 
(E-H) Phosphorylation of ERK (Thr202/Tyr204), GSK-3β (Ser9) and Akt (Thr308 and Ser473) in 
mouse melanoma cells. B16/F10 were allowed to adhere to C1q, FN and FN+C1q and the phosphorylation 
status of ERK1, GSK-3β and Akt and was evaluated on total cell lysates as described in Materials and 
Methods. 
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DISCUSSION 
 
The tumour microenvironment comprising infiltrating immune and non-
immune cells as well as the extracellular matrix undergoes substantial changes during 
cancer development that may largely influence tumour progression (Swartz et al., 2012; 
Junttila and de Sauvage, 2013). A recently discovered function of complement activation 
products released at tumour site is to recruit myelomonocytic cells that suppress the 
adaptive immune response to tumour antigens and promotes tumour growth (Markiewski 
et al., 2008). This novel aspect of the complement activity in tumour-host interaction have 
disclosed a dual and opposing role of this system (Loveland and Cebon, 2008; Stover, 
2010). Besides being effective in cancer immunosurvaillance, using complement fixing 
mAbs to tumour associated antigens combined with CRPs neutralizing Abs (Macor et al., 
2015), favours tumour growth in situation of slow and chronic C activation (Rutkowski et 
al., 2010). The data presented in this study indicate that C1q contributes to changes of 
tumour microenvironment acting as an external component of the extracellular matrix and 
favouring tumour growth and invasion. 
Deposits of C components have been reported in different human tumours by various 
groups and interpreted as the results of complement activation induced by several 
triggering factors including antibodies to tumour associated antigens, immune complexes, 
and cell damaged by necrosis and apoptosis (Stover, 2010; Pio et al., 2014). The extent of 
complement activation, that in some cases proceeds to the assembly of the terminal 
complex (Vlaicu et al., 2013), is probably dependent on the tumour type, and the degree of 
inflammation associated with tumour invasion. C1q was the predominant complement 
component deposited in all tumour examined in this study and its localization on 
endothelial cells and stroma is reminiscent of a similar distribution in human decidua 
where is locally synthesized and secreted by several cells including endothelial cells and 
trophoblast (Bulla et al., 2008; Agostinis et al., 2010). 
Although C1q deposition is usually regarded as an indication of classical pathway 
activation, our failure to detect C4 in all tumours and C1s in most of them makes this an 
unlikely possibility and rather suggests an alternative mechanism of C1q involvement at 
tumour site not necessarily related to complement activation. Data accumulated in recent 
years have revealed non canonical functions exerted by C1q on cells of both innate and 
adaptive immunity (Nayak et al., 2010, 2012; Ghebrehiwet et al., 2012), as well as on cells 
selectively localized in some tissues, such as microglial cells in the central nervous system 
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and trophoblasts in placental decidua (Veerhuis et al., 2011; Agostinis et al., 2010). The 
level of  this recognition molecule of the complement system has been reported  to increase 
substantially in aging brain and to contribute to age-related cognitive decline (Stephan et 
al., 2013). In pregnancy C1q has been implicated in tissue remodelling in maternal decidua 
required for successful embryo implantation (Bulla et al., 2012). 
The critical role of C1q in tumour development is supported by the finding of prolonged 
survival, and slower progression, of tumour growth in C57BL/6.C1qa-/- bearing a 
syngeneic B16/F10 melanoma, as compared to WT mice. Failure to detect significant 
difference in tumour growth and survival between C3-/- and WT mice excludes the 
possibility that the cancer promoting effect of C1q was dependent on complement 
activation. This conclusion is further supported by the immunofluorescence analysis of the 
tumour mass developed in WT mice, which revealed marked deposition of C1q on vascular 
endothelium and stroma in complete absence of C4, while staining for C3 was almost 
exclusively restricted to CD68+ cells. C5-/- mice was included in this study as a control 
group because previous reports have shown that C5a generated through local complement 
activation promotes tumour growth by recruiting myeloid-derived suppressor cells 
(MDSCs) that inhibit T cell-mediated anti-tumour response (Markiewski et al., 2008; 
Rutkowski et al., 2010). The finding that melanoma grew in C5-/- mice in a manner similar 
to that observed in C3-/- and WT mice further rules out the contribution of complement 
activation products and more specifically of C5a to tumour progression. The potential 
contribution of C1q to modulate the anti-tumour immune response was excluded by the 
analysis of peri-tumoural cell infiltrates that revealed no difference in the percentage of 
effector T cells, NK cells, macrophages and myeloid derived suppressor cells between 
C1qa-/- and WT mice.  
The ex vivo and in vivo data pointed to a direct contribution of C1q to tumour growth 
independent of complement activation and raised the question of whether locally produced 
C1q was responsible for its cancer promoting effect. Although several cell types may 
synthesise C1q, it was unclear which cells were implicated in this process. The answer was 
obtained from the analysis of tumour development in bone marrow transplanted mice. 
Surprisingly, bone marrow from WT mice, despite the ability to reconstitute normal C1q 
serum level in C1qa-/- animals, had only a negligible effect on tumour growth in C1q-
deficient mice, suggesting that non bone marrow-derived cells were the relevant source of 
C1q needed for its tumour promoting activity. Included in this group of cells, besides 
stroma cells, are endothelial cells that exhibited strong C1q staining in tumour developed 
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in WT mice. Serum is an unlikely source of C1q bound to endothelial cells because tumour 
ECs from WT mice reconstituted with C1qa-/- bone marrow cells still express C1q despite 
its nearly undetectable level in the circulation. Moreover, our failure to detect C4 on ECs 
both in human tumours and in the animal model of melanoma tend to exclude that C1q 
deposition is the result of complement activation. An alternative possibility to explain C1q 
expression on the surface of ECs is that these cells start synthesizing and secreting C1q in 
response to developing tumour. Although this issue was not specifically addressed, we 
have collected evidence from our previous studies indicating ECs may acquire the ability 
to produce C1q at some tissue sites and in certain pathophysiologic conditions like 
decidual endothelial cells in pregnancy (Bulla et al., 2008) and dermal microvascular 
endothelial cells in wound healing (Bossi et al., 2014). 
The finding that C1q was localized on ECs of newly formed vessels identified by CD34 
expression in the tumour tissue led us to hypothesize a possible contribution of C1q to the 
induction of angiogenesis. We were justified in pursuing this issue by our published work 
showing that C1q exhibits angiogenic activity promoting skin wound healing (Bossi et al., 
2014). Consistent with these observations is the increased number of vessels observed both 
within the tumour mass and in the peritumoral area. As melanoma is considered a highly 
angiogenic tumour that exploits newly formed vessels to receive oxygen and nutrients and 
to establish metastasis (Emmett et al., 2011; Braeuer et al., 2014), it is not surprising to see 
larger metastatic areas in tumour bearing WT mice compared to C1qa-/- mice.  
By interacting with proteins of the extracellular matrix like fibronectin, C1q offers an 
anchor to tumour cells for their initial seeding. The pro-adhesive effect of C1q does not 
seem to be restricted to the primary tumour, but can also be seen at metastatic sites as 
suggested by its presence at lung metastases of colon carcinoma. As already seen with 
trophoblasts (Agostinis et al., 2010), melanoma cells tend to bind loosely to C1q making it 
easier for cells to move toward surrounding stromal areas expressing this complement 
component. However, the tumour cells would not have much chance of expanding if they 
were not stimulated by C1q to proliferate as clearly documented by our data.  
C1q signals B16/F10 cells stimulating the phosphorylation status of ERK, Akt and GSK-
3β possibly as a result of interaction with gC1qR and α4β1 integrin expressed on these 
cells (Park et al., 2012; Prakash et al., 2011; Ratheesh et al., 2007; Zhao et al., 2008). 
These receptors have been shown to be engaged by C1q on the surface of trophoblasts 
leading to activation of ERK1/2 MAPKs and enhanced adhesion and migration of these 
cells (Agostinis et al., 2010). Evidence has been collected indicating that MAPK/ERK, 
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PI3K/Akt/GSK-3β and Wnt/GSK-3β signalling pathways are often activated in cancer and 
cooperate to promote cancer progression and metastasis (Anastas and Moon, 2013; 
McCubrey et al., 2012, 2014). 
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CONCLUSION 
 
In conclusion, evidence collected from human tumours revealed a constant 
presence of C1q, which was mainly localized in the stroma and on vascular endothelium in 
the absence of C4. A reduced tumour size and a prolonged animal survival were 
documented in a syngeneic melanoma model developed in C1q-deficient mice compared to 
tumour established in WT, as well as in C3 and C5 deficient mice. Our data support the 
conclusion that C1q favours tumour growth and metastases, facilitating cancer cell seeding 
and invasion, through promotion of angiogenesis and sustain the activation of cancer-
related signalling pathways. 
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